

Sid Gilman, M.D., F.R.C.P.
William J. Herdman Distinguished University Professor of Neurology
Director, Michigan Alzheimer's Disease Research Center
300 N. Ingalls Street, Room 3D15, SPC 5489
734-936-1808
sgilman@umich.edu

Title and Contents	Page 1
Education and Training	Page 2
Certification and Licensure	Page 2
Academic, Administrative, and Clinical Appointments	Page 2
Research Interests	Page 3
Grants	Page 3
Honors and Awards	Page 5
Memberships in Professional Societies	Page 5
Editorial Positions, Boards, and Peer-Review Service	Page 6
Teaching	Page 9
Committee, Organizational, and Volunteer Service	Page 9
Consulting Positions	Page 9
Visiting Professorships, Seminars, and Extramural Invited Presentations	Page 10
Bibliography	Page 11

Sid Gilman, M.D., F.R.C.P.
William J. Herdman Distinguished University Professor of Neurology
Director, Michigan Alzheimer's Disease Research Center
300 N. Ingalls Street, Room 3D15, SPC 5489
734-936-1808
sgilman@umich.edu

Education and Training

High School:	09/1947-06/1950	Huntington Park High School Huntington Park, CA
Undergraduate:	09/1950-06/1953	College of Letters and Science University of California at Los Angeles
	06/1954	Bachelor of Arts
Medical School:	09/1953-06/1957	School of Medicine University of California at Los Angeles
	06/1957	Doctor of Medicine
Internship:	07/1957-06/1958	Internal Medicine, University of California Hospital, Los Angeles
Research Training:	07/1958-06/1960	Research Associate in Neurophysiology, National Institute of Neurological Diseases and Blindness, National Institutes of Health, Bethesda, Maryland
Neurology Residency	07/1960-06/1963	Neurological Unit, Boston City Hospital (and Teaching Fellow in Neurology, Harvard Medical School)
Research Fellowship	07/1963-06/1965	Harvard Medical School at the Neurological Unit, Boston City Hospital

Certification and Licensure

1966 American Board of Psychiatry and Neurology
1977 State of Michigan License # 4301038961 Valid through 1/31/09
1958 State of Maryland License # D02891 Currently inactive
1957 State of California License #A018175 Currently inactive
1960 State of Massachusetts License #26642 Currently inactive
1968 State of New York License #100595 Currently inactive

Academic, Administrative, and Clinical Appointments

07/1965-06/1966	Instructor in Neurology, Harvard Medical School
07/1966-06/1968	Associate in Neurology, Harvard Medical School
04/1968-06/1970	Assistant Professor of Neurology, Columbia University
04/1968-06/1970	Assistant Attending Neurologist, Presbyterian Hospital
07/1970-06/1972	Associate Professor of Neurology, Columbia University
07/1970-06/1972	Associate Attending Neurologist, Presbyterian Hospital

07/1970-06/1974	Attending Neurologist, St. Barnabas Hospital, New York
07/1972-06/1976	Professor of Neurology, Columbia University
07/1972-08/1977	Attending Neurologist, Presbyterian Hospital
07/1976-06/1977	H. Houston Merritt Professor in Neurology, Columbia University
07/1977-08/1977	H. Houston Merritt Professor in Neurology and Professor of Anatomy, Columbia University
09/1977-03/2004	Professor and Chair, Department of Neurology, University of Michigan
09/1977-03/2004	Chief, Neurology Service, University of Michigan Hospitals
09/1977-	Physician (Consultant), Veterans Administration Hospital Ann Arbor, Michigan
07/1980-06/1984	Adjunct Attending Neurologist, Henry Ford Hospital, Detroit, Michigan
07/1991-	Director, Michigan Alzheimer's Disease Research Center
07/1997-	William J. Herdman Professor, Department of Neurology, University of Michigan
04/2004-	Attending Neurologist, University of Michigan Hospitals
09/2005-	William J. Herdman Distinguished University Professor of Neurology, University of Michigan

Research Interests

1. Molecular imaging with positron emission tomography in Alzheimer's disease, Parkinson's disease, multiple system atrophy.
2. Autonomic failure in the alpha synucleinopathies Parkinson's disease, Lewy body disease and multiple system atrophy
3. Rapid eye movement sleep behavior disorder in the alpha synucleinopathies
4. Cardiac denervation in the alpha synucleinopathies
5. Immunotherapy for disease modification in Alzheimer's disease

Grants

Present and Active Grant Support

NIH-NIA P50 AG08671 Michigan Alzheimer's Disease Research Center, 7-1-06 to 6-30-11, Sid Gilman, Program Director, current year \$888,000 (direct costs); Core A, Administrative Core, Sid Gilman, Principal Investigator, current year \$98,621 (10% effort).

NIH-U01-AG16976 Alzheimer's Disease Coordinating Center, 7-01-05 to 6-30-11, Sid Gilman, Principal Investigator, current year \$25,000 (direct costs) (0% effort).

NIH-NINDS, P01 NS15655 PET Study of Biochemistry and Metabolism of the CNS, 7-1-08 to 6-30-12, Kirk A. Frey, Program Director, current year \$1,258,100 (direct costs); Project 4, Autonomic Disorders in Parkinson Disease, Sid Gilman, Principal Investigator, current year \$72,815 (15% effort).

NIH-NINDS, 2 P01 NS044233 Pathogenesis and diagnosis of multiple system atrophy, 7-1-10 to 6-30-15, Phillip A. Low, Program Director, current year TBD, Project 1, Longitudinal Course of MSA, current year 253,976, Sid Gilman, Principal Investigator (15% effort), Core A (Administrative Core), 19,450, Sid Gilman, Co-Principal Investigator (5% effort).

GE Healthcare, 067-005, A principal open-label study to assess the prognostic usefulness of Flutemetamol (18F) injection for identifying subjects with amnesic mild cognitive impairment who will convert to probable Alzheimer's disease, 4-1-10 to 3-31-12, Kirk Frey, Principal Investigator, Sid Gilman Co-Principal Investigator (25% effort) total project funds \$373,438.00.

GE Healthcare, 067-007, A principal, prospective, open-label study to compare the brain uptake of [¹⁸F]Flutemetamol with brain amyloid levels determined post-mortem, 10-1-10 to 9-3-12, Kirk Frey, Principal Investigator, Sid Gilman Co-Principal Investigator (25% effort) total project funds to be determined.

Previous Grant Support

NIH-NINDB F11 NB1002 Special Fellowship, Sid Gilman, 1962-1966

NIH-NINDB K3 NB31105 Research Career Development Award, Sid Gilman, 1966-1968

NIH-NINDB RO1 NB04610 D. Denny-Brown, Principal Investigator 1964-1966; Sid Gilman, Principal Investigator 1966-1968

NIH-NINCDS P50 NS05184 M.D. Yahr, Program Director, Sid Gilman, Principal Investigator, Project 4, 1968-1972

NIH-NINCDS RO1 NS10612 Sid Gilman, Principal Investigator, 1974-1977

NIH-NINCDS RO1 NS11981 Sid Gilman, Principal Investigator, 1974-1977

NIH-NINCDS RO1 NS11307 Sid Gilman, Principal Investigator, 1974-1977

NIH-NINDS PO1 NS19613 Sid Gilman, Program Director and Principal Investigator, Project 1 and Core A, 1984-1994

NIH-NINDS PO1 NS15655 David E. Kuhl, Program Director; Sid Gilman, Principal Investigator, Project 4, 1979-1994

NLM RO1 LM05466 Joel Vilensky, Principal Investigator, Sid Gilman, Co-Principal Investigator, 1993-1995

Lucille P. Markey Charitable Trust, Molecular Biology and Regulation, 1988 to 1997, Sid Gilman and Bernard W. Agranoff, Co-Directors, Sid Gilman, PI, Project 4.

NIH-NIAAA, PO1 AA07378, Robert Zucker, Program Director, Sid Gilman, Principal Investigator, Project 1, 1988-1998.

NIH-NIA, R25 AG11219, Cathleen M Connell, Program Director, Sid Gilman, Co-Director, 1992-1998.

US HHS-PHS HRSA Contract #981846, Dementia Assessment Education Program, Michigan Department of Community Health 10/01/00 to 9/30/01, Sid Gilman, Principal Investigator.

NIH-NINDS, 5 T32 NS07222, Training in Basic and Clinical Neuroscience, 7-1-82 to 6-30-02, Sid Gilman, Program Director.

Michigan Department of Community Health #N002987, Long Term Care Innovations, 10/01/01 to 9/30/04, Sid Gilman, Principal Investigator.

NINDS, 1 RO1 NS33782, Evaluation of the Denny-Brown Research Collection, 01-01-95 to 12-31-04, Joel Vilensky, Principal Investigator, Sid Gilman, Co-Principal Investigator.

NIH-NIA P50 AG08671 Michigan Alzheimer Disease Research Center, 9-29-89 to 5-31-05, Sid Gilman, Program Director, Project 1, Motor Correlates of Dementia, Sid Gilman, Principal Investigator, Core A, Administrative Core, Sid Gilman, Principal Investigator.

NIH-NINDS, P01 NS15655 PET Study of Biochemistry and Metabolism of the CNS, 7-1-01 to 6-30-06, Kirk A. Frey, Program Director, current year \$971,276 (direct costs); Project 3, Neurochemical and Sleep Disorders in Multiple System Atrophy, Sid Gilman, Principal Investigator, current year \$76,222 (20% effort).

NIH-NINDS P01 NS044233 Pathogenesis and Diagnosis of Multiple System Atrophy, 9/30/03 to 6/30/09, Clifford Shults, Program Director, current year \$1,798,890 (direct costs); Sid Gilman, Enrolling Site Investigator, Consultant to Core A \$28,000 (3% effort).

Cortex Pharmaceuticals, Inc. A Pilot, Randomized, Double-Blind, Three-Way Crossover Study To Assess The Efficacy And Safety Of Single Administrations Of Different Dosage Strengths Of The Ampakine[®] Compound, Cx717, Versus Placebo On Measures Of Regional Cerebral Blood Flow And Cognitive Function In A Population Of Patients With Alzheimer's Disease And Matched Normal Volunteers, 7/01/05 to 7/01/08, Sid Gilman, Principal Investigator, current year \$632,369 (direct costs) (10% effort)

Honors and Awards

1953	First Place, State of California Gymnastics Tournament, Free Exercise
1954	Tenth Place, NCAA Gymnastics Tournament, Free Exercise
1954	Highest Honors at Graduation, UCLA, Phi Beta Kappa
1957	Highest Honors at Graduation, UCLA School of Medicine, Alpha Omega Alpha
1957-1958	Ambrose and Gladys Bowyer Foundation Fellow in Medicine
1962-1966	Special Fellow, National Institutes of Health
1966-1968	Research Career Development Award, National Institutes of Health
1973	Lucy G. Moses Prize in Basic Neurology
1981	United Cerebral Palsy Weinstein-Goldenson Award for Medical Research for Cerebral Palsy and the Physically Handicapped
1986-1988	President, Michigan Neurological Association
1988-1989	President, American Neurological Association
1992	UCLA Alumni Professional Achievement Award
1992	UCLA Medical Alumni Professional Achievement Award
1995	Member, Institute of Medicine, National Academy of Sciences
1997	Honorary Member, American Neurological Association
1999	Fellow, American Association for the Advancement of Science
2000	Fellow, Royal Society of Medicine
2001	Fellow, Royal College of Physicians
2001	Fellow, American Academy of Arts and Sciences
2002	National Associate, The National Academies (National Academy of Sciences, National Academy of Engineering, Institute of Medicine, National Research Council)
2003	Neurology Service, University of Michigan Hospitals, named the Sid Gilman Service
2004	Sid Gilman and Carol Barbour Annual Lecture in Fundamental Neurology established by the Department of Neurology
2004	AB Baker Award for Lifetime Achievement in Neurologic Education (American Academy of Neurology)

2004 Member, Association of American Physicians
2005 William J. Herdman Distinguished University Professor of Neurology,
University of Michigan
2010 Medical Center Alumni Society Distinguished Achievement Award,
University of Michigan

Memberships in Professional Societies

American Academy of Neurology (Chair, Decade of the Brain Committee, 1990-1995; Chair, Geriatric Neurology Section, 1994-1996)
American Academy of Arts and Sciences (Fellow 2001)
American Association for the Advancement of Science (Fellow 1998)
American Association of Neuropathologists
American Association of University Professors
American Epilepsy Society
American Neurological Association (Vice President 1981-82 and 1985-1986; President-elect 1987-1988; President 1988-89)
American Physiological Society
American Society for Clinical Investigation
Association for Research in Nervous and Mental Disease
Association of American Physicians
Fellow, Harvey Society
Institute of Medicine, National Academy of Sciences (Member 1995, National Associate 2002)
International Medical Society of Motor Disturbances (ISMD)
Massachusetts Medical Society
Medical Society of the County of New York
Michigan Neurological Association (President 1986-1988)
Movement Disorder Society
New York Academy of Sciences
Pan American Medical Association
Royal College of Physicians, Fellow
Royal Society of Medicine, Fellow
Sigma Xi (Kappa Chapter)
Society for Cerebral Blood Flow & Metabolism
Society for Neuroscience
American Society for Experimental Therapeutics
International Society to Advance Alzheimer Research and Treatment

Editorial Postions, Boards, and Peer-Review Service

Previous Editorial Board Positions

1972-1976 Editorial Board, *Neurology*
1973-1981 Advisory Board, *Journal of Neuropathology and Experimental Neurology*
1974-1982 Editorial Board, *Applied Neurophysiology*

1980-1997	Editorial Board, <i>Experimental Neurology</i>
1981-1987	Editorial Board, <i>Annals of Neurology</i>
1982-1994	Editorial Board, <i>Contemporary Neurology Series</i> F.A. Davis Company, Publishers
1992-1999	Editorial Board, <i>Neurobase</i> , Arbor Publishing Corporation
1994-1998	Editor-in-Chief, <i>Contemporary Neurology Series</i> F.A. Davis Company, Publishers
1995-2000	Editor-in-Chief, <i>Neurology Network Commentary</i> Churchill Livingstone
1997-2003	Section Editor, Neurology and Psychiatry, <i>Experimental Neurology</i> Academic Press
2000-2002	Editor-in-Chief, <i>Lancet Neurology Network</i> , The Lancet Publications
1993-2005	Editorial Board, <i>Neurobiology of Disease</i> , Elsevier
1994-2007	Editorial Board, <i>Alzheimer Disease & Associated Disorders: An International Journal</i> , Lippincott Williams & Wilkins
2005-2010	Editor-in-Chief, <i>Neurobiology of Disease</i> , Elsevier

Current Editorial Board Positions

1990-	Editorial Board, <i>Current Opinion in Neurology</i> , Lippincott Williams & Wilkins
1992-	Editorial Board, <i>Advances in Neurology</i> , Lippincott Williams & Wilkins
1998-	Editor-in-Chief, <i>Contemporary Neurology Series</i> , Oxford University Press
1999-	Editor-in-Chief, <i>MedLink Neurology</i> , MedLink Corporation
2000-	Editorial Board, <i>Clinical Neuroscience Research</i> , Elsevier Publications
2001-	Editorial Board, <i>Cerebellum</i> , Cambridge University Press
2003-	Editor-in-Chief, <i>Experimental Neurology</i> , Elsevier
2009	Editorial Board, <i>European Neurological Journal</i> , San Lucas Medical

Previous Advisory Committees

1971-1973	Neurological Sciences Research and Training Committee, National Institute of Neurological Diseases and Stroke
1973-1996	Research Advisory Council, United Cerebral Palsy Research and Educational Foundation, Inc.
1976-1984	Professional Advisory Board, Epilepsy Foundation of America
1976-1980	Neurological Disorders Program Project Review B Committee, National Institutes of Health
1978-1982	Professional Advisory Council, United Cerebral Palsy Association of Michigan
1978-1984	Scientific Advisory Council, National ALS Foundation, Inc.
1982-1984	Scientific Programs Advisory Committee, National Institute of Neurological, Communicative Disorders and Stroke, National Institutes of Health
1985-1986	Scientific Advisory Council, Amyotrophic Lateral Sclerosis Association

1986-1987 Michigan Task Force on Alzheimer's Disease and Related Conditions; Chairman, Committee on Epidemiology, Research and Training; Member, Task Force Steering Committee

1986-1989 Research Advisory Committee, National Multiple Sclerosis Society

1986-1992 Appeals Panel, Accreditation Council for Graduate Medical Education

1988-1990 Neurology Intersociety Liaison Committee, Member; Chairman 1989-90

1988-1994 The Michigan Department of Public Health, Chronic Disease Advisory Committee; Chairman, Subcommittee on Dementias

1989-1994 National Coalition for Research and National Foundation for Brain Research, Executive Board Member

1990-1994 Decade of the Brain Committee, American Academy of Neurology, Chair

1992-1993 Agency for Health Care Policy and Research; Member, Panel to Develop Guidelines for Screening for Alzheimer's Disease

1992-1992 National Task Force to Develop a Strategic Plan for the National Institutes of Health; Co-Chair, Cost Management Panel

1994-2000 Michigan Dementia Program, Michigan Department of Community Health, Chair

1994-1997 National Advisory Neurological Disorders and Stroke Council, National Institutes of Health, Member

1995-1997 Council/Board Representatives to Director, National Institutes of Health, Chair

1995-1997 Scientific Advisory Committee, Parkinson Study Group, Member and Chair

1995-1997 Public Policy Committee, American Neurological Association, Member

1998-1999 Institute of Medicine, National Academy of Sciences Committee on the NIH Research Priority-Setting Process, Member

1999-2000 Institute of Medicine, National Academy of Sciences Committee on Building Bridges in the Brain, Behavioral and Clinical Sciences, Member

2001-2003 National Institutes of Health Search Committee to select a Director, National Institute of Neurological Disorders and Stroke, Member

2002-2004 American Neurological Association Program Advisory Committee, Member

2001-2005 Institute of Medicine, National Academy of Sciences Board on Neuroscience and Behavioral Health, Vice-Chair

2001-2004 National Institute of Neurological Disorders and Stroke Council Clinical Trials Subcommittee, Member

2002-2005- National Alzheimer's Disease Coordinating Committee, Steering Committee, Member

2006-2007 Institute of Medicine Committee on Medical Evaluation of Veterans for Disability Compensation, Member

2006 Doris Duke Charitable Foundation, Grants Advisory Committee, Member

2007 Michael J. Fox Foundation Grant Review Committee, Member

2007 Metabolic and Endocrine Committee, Food and Drug Administration, to evaluate Rimnabant, Member

2007-2009 Chair, Interest Group 03 on Neuroscience, Behavior, Brain Function and Disorders, Institute of Medicine, National Academy of Sciences
2008 Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee, Food and Drug Administration, to Evaluate Antiepileptic Drugs and Suicidality, Member

Current Advisory Committees

1983- Food and Drug Administration, Peripheral and Central Nervous System Drugs Advisory Committee, (Member, 1983-1985, 1986-1987, and 1990-1993) (Consultant, 1985-1986, 1987-1990, 1993-1995, 1995-1996); (Chair, 1996-2000) Consultant 2000-2015
1986- National Ataxia Foundation, Medical and Research Advisory Board, Member

Teaching

Outpatient clinical teaching of neurology, pediatric neurology and neurosurgery residents, and medical students, 1977-

Inpatient and Neurology Consultation Service teaching, neurology, pediatric neurology and neurosurgery residents and medical students, 1977-

Committee, Organizational, and Volunteer Service

Appointments, Promotions, and Awards Committee, Department of Neurology
Bed and Clinic Utilization Committee, University of Michigan Hospitals
Clinical Chairs' Advisory Council, University of Michigan Medical School
Clinical Council, University of Michigan Hospitals
Clinical Services Committee, Department of Neurology
Dean's Advisory Council, University of Michigan Medical School
Faculty Recruitment Committee, Department of Neurology, University of Michigan
University of Michigan Geriatric Center Steering Committee
University of Michigan Cancer Center Steering Committee
Geriatric Research, Education and Clinical Center, External Review Committee and Advisory Committee
Institute of Gerontology, Executive Board Member
Michigan Alzheimer's Disease Research Center Executive Committee
MSP Executive Committee, University of Michigan Medical School
Medical Scientist Training Program (MSTP) Policy Committee
Medical Science Research Building III Advisory Committee
Neuroscience Laboratory Building Operations Committee
Positron Emission Tomography/Cyclotron Center Executive Committee
Residency Recruitment Committee, Department of Neurology
Training Grant Executive Committee, Department of Neurology

Ann Arbor Veterans Affairs Medical Center Dean's Committee
Member, Heritage Foundation Advisory Board

Consulting Positions

Previous Consulting Positions

1989-1993	Regeneron Pharmaceuticals, Consultant
2000-2004	Merck & Co, Inc. External Scientific Advisory Board, Member
2000-2006	INC Research, Scientific Advisory Board, Member
2001-2003	Elan/Wyeth Pharmaceuticals, Safety Monitoring Committee, Phase II trials of AN1792 vaccination for Alzheimer's disease, Chair
2003-2008	NeuroMolecular (now Adamas) Scientific Advisory Board, Member
2004-2006	Science Partners, Member
2004-2007	ReNeuron, Clinical Advisory Board, Chair
2005-2007	Pequot Capital, Scientific Advisory Board, Member
2005-2008	Johnson & Johnson, Independent Data Monitoring Committee for clinical trials, Topiramate Pediatric Epilepsy Program, Chair
2007-2008	Balboa Biosciences, Board of Directors, Member
2005-2008	Wyeth Neuroscience Global Steering Committee, Member
1999-2008	PPD Development, Scientific Advisory Board, Member
2008-2008	Johnson & Johnson, Consultant
2008-2008	Sierra Neuropharmaceuticals, Consultant
2008-2010	Elan/Transition Therapeutics, Independent Safety Monitoring Committee, Phase II trials of Scyllo-Inositol for Alzheimer's disease, Chair
2009-2009	GlaxoSmithKline China Research, Scientific Advisory Board, Member

Current Consulting Positions

2002-	Gerson Lehrman Group Scientific Advisory Board, Member
2003-	Elan/Wyeth (Janssen/Pfizer effective 9/15/09) Safety Monitoring Committee, Phase I, II and III trials of passive immunization with AAB-001 for Alzheimer's disease, Chair
2007-	Longitude Capital, Scientific Advisory Board, Member
2009-	Teva Neuropharmaceuticals, Member, Steering Committee, Phase II trial of Rasagiline in MSA
2009-	Allergan Phase II trial of local peptide therapy for pain
2010	TPP Scientific Advisory Board, Chair
2010	Pfizer Safety Monitoring Committee, Phase I Safety Monitoring Committee, Phase I trial of passive immunization with AAB-003 for Alzheimer's disease, Chair

Named Visiting Professorships, Seminars, and Extramural Invited Presentations

1989	Harvard-Longwood-Brigham and Women's Hospital Visiting Professor, Boston, Massachusetts
1989	Merritt-Putnam Visiting Professor, University of Texas Southwestern Medical Center, Dallas, Texas
1991	G. Milton Shy Visiting Professor, Columbia University, University of Pennsylvania, National Institutes of Health, New York, Philadelphia, Bethesda
1992	Robert Aird Visiting Professor, University of California, San Francisco, California
1993	Vivian L. Smith Visiting Professor, Baylor College of Medicine, Houston, Texas
1994	Robert Wartenberg Lecturer, American Academy of Neurology
1994	Sigma Tau Foundation Lecturer on Aging, Rome, Italy
1996	Ellery Sedgwick, Jr. Visiting Professor, Case Western Reserve University, Cleveland, Ohio
1998	William S. Fields Lecture, University of Texas, Houston, Texas
1999	The Nineteenth T.S. Srinivasan Endowment Lecture, Madras, India
1999	Bernard Rogowsky Lecture, Yale University, New Haven, Connecticut
2001	Henry Russel Lecture, University of Michigan, Ann Arbor, Michigan
2004	John B. Penney Lecture, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
2008	Keynote speaker, 100 th anniversary, Swiss Neurological Society, Montreux, Switzerland
2009	Utterback Professor, University of Tennessee Health System
2010	Kirshner Lecture, Vanderbilt University

Bibliography

Peer-Reviewed Journals and Publications

1. Gernandt BE, Gilman S: Descending vestibular activity and its modulation by proprioceptive, cerebellar, and reticular influences. *Exp Neurol* 1959;1:274-304.
2. Gernandt BE, Gilman S: Vestibular and propriospinal interactions and protracted spinal inhibition by brain stem activation. *J Neurophysiol* 1960;23:269-287.
3. Gernandt BE, Gilman S: Interactions of vestibular, pyramidal, and cortically evoked extrapyramidal activities. *J Neurophysiol* 1960;23:516-533.
4. Gernandt BE, Gilman S: Differential supraspinal control of spinal centers. *Exp Neurol* 1961;3:307-324.
5. Gilman S, Braverman LE, Starr A, Horenstein S, Tilles JG: Intracranial aneurysm causing panhypopituitarism, blindness, seizures, and dementia. *Ann Int Med* 1962;57:639-646.
6. Gilman S, MacFadyen DJ, Denny-Brown D: Decerebrate phenomena after carotid amobarbital injection. *Arch Neurol* 1963;8:662-675.
7. Gilman S, Horenstein S: Familial amyotrophic dystonic paraplegia. *Brain* 1964;87:51-66.
8. Gilman S: Cerebral disorders after open heart operations. *New Eng J Med* 1965;272:489-498.

9. Van Der Meulen JP, Gilman S: Recovery of muscle spindle activity in cats after cerebellar ablation. *J Neurophysiol* 1965;28:943-957.
10. Gilman S, Van Der Meulen JP: Cryogenic decerebration. *Arch Neurol* 1965;13:297-306.
11. Gilman S, Van Der Meulen JP: Muscle spindle activity in dystonic and spastic monkeys. *Arch Neurol* 1966;14:553-563.
12. Gilman S, Denny-Brown D: Disorders of movement and behaviour following dorsal column lesions. *Brain* 1966;89:397-418.
13. Gilman S, McDonald WI: Cerebellar facilitation of muscle spindle activity. *J Neurophysiol* 1967;30:1494-1512.
14. Gilman S, McDonald WI: Relation of afferent fiber conduction velocity to reactivity of muscle spindle receptors after cerebellectomy. *J Neurophysiol* 1967;30:1513-1522.
15. McDonald WI, Gilman S: Demyelination and muscle spindle function. Effect of diphtheritic polyneuritis on nerve conduction and muscle spindle function in the cat. *Arch Neurol* 1968;18:508-519.
16. Gilman S: A crossed cerebellar influence on muscle spindle primaries. *Brain Res* 1968;8:216-219.
17. Gilman S: Fusimotor fiber responses in the decerebellate cat. *Brain Res* 1969;14:218-221.
18. Gilman S: The mechanism of cerebellar hypotonia: An experimental study in the monkey. *Brain* 1969;92:621-638.
19. Ebel HC, Gilman S: Estimation of errors in conduction velocity measurements due to branching of peripheral nerve fibers. *Brain Res* 1969;16:273-276.
20. Gilman S, Ebel HC: Fusimotor neuron responses to natural stimuli as a function of prestimulus fusimotor activity in decerebellate cats. *Brain Res* 1970;21:367-384.
21. Gilman S, Marco LA: Effects of medullary pyramidotomy in the monkey. I. Clinical and electromyographic abnormalities. *Brain* 1971;94:495-514.
22. Gilman S, Marco LA, Ebel HC: Effects of medullary pyramidotomy in the monkey. II. Abnormalities of muscle spindle afferent responses. *Brain* 1971;94:515-530.
23. Potegal M, Copack P, de Jong JMBV, Krauthamer G, Gilman S: Vestibular input to the caudate nucleus. *Exp Neurol* 1971;32:448-465.
24. Gilman S, Lieberman JS, Copack P: A thalamic mechanism of postural control. *Int J Neurol* 1971;8:260-275.
25. Ebel HC, Gilman S, Marco LA: Analysis of neural unit-data: Effect of threshold upon average response frequency. *Brain Res* 1972;44:265-270.
26. Dafny N, Gilman S: L-DOPA and reserpine: Effects on evoked potentials in basal ganglia of freely moving rats. *Brain Res* 1973;50:187-191.
27. Marco LA, Copack P, Edelson AM, Gilman S: Intrinsic connections of caudate neurons. I. Locally evoked field potentials and extracellular unitary activity. *Brain Res* 1973;53:291-305.
28. Gilman S, Barrett RE: Hallervorden-Spatz disease and infantile neuroaxonal dystrophy: Clinical characteristics and nosological considerations. *J Neurol Sci* 1973;19:189-205.
29. Marco LA, Ebel HC, Sommers D, Gilman S: Abnormalities of muscle spindle afferent responses in congenital feline ataxia. *Exp Brain Res* 1973;17:111-123.
30. Dafny N, Gilman S: Characterization of single unit activity in hypothalamus and reticular formation recorded with semi- microelectrodes. *Brain Res* 1973;59:243-255.

31. Dafny N, Phillips MI, Taylor AN, Gilman S: Dose effects of cortisol on single unit activity in hypothalamus, reticular formation, and hippocampus of freely behaving rats correlated with plasma steroid levels. *Brain Res* 1973;59:257-272.
32. Lieberman JS, Copack PB, Gilman S: Fusimotor effects of cryogenic lesions in ventrolateral nucleus and pulvinar. *Arch Neurol* 1974;30:375-384.
33. Dafny N, Gilman S: Alteration of evoked potentials in caudate nucleus of freely moving rats by L-DOPA, reserpine, and pentobarbital. *Exp Neurol* 1974;42:51-64.
34. Gilman S, Lieberman JS, Marco LA: Spinal mechanisms underlying the effects of unilateral ablation of areas 4 and 6 in monkeys. *Brain* 1974;97:49-64.
35. Dafny N, Gilman S: Monoamine effects on neuronal recovery cycles in globus pallidus, caudate nucleus, and substantia nigra. *J Neural Trans* 1974;35:275-281.
36. Gilman S, Dauth GW, Tennyson VM, Kremzner LT: Chronic cerebellar stimulation in the monkey: Preliminary observations. *Arch Neurol* 1975;32:474-477.
37. Copack PB, Felman E, Lieberman JS, Gilman S: Differences in proximal and distal conduction velocities of efferent nerve fibers to the medial gastrocnemius muscle. *Brain Res* 1975;91:147-150.
38. Tennyson VM, Kremzner LT, Dauth GW, Gilman S: Chronic cerebellar stimulation in the monkey: Electron microscopic and biochemical observations. *Neurology* 1975;25:650-654.
39. Potegal M, Abraham L, Gilman S, Copack P: A technique for vestibular neurotomy in the rat. *Physiol Behav* 1975;14:217-221.
40. Dafny N, Dauth G, Gilman S: Differential effects of agents which alter CNS monoamine levels upon acoustic responses in the basal ganglia of freely moving rats. *Int J Neurol* 1975;10:53-67.
41. Copack PB, Lieberman JS, Gilman S: Alpha motoneuron responses to natural stimuli in decerebellate cats. *Brain Res* 1975;95:75-87.
42. Dafny N, Dauth G, Gilman S: A direct input from amygdaloid complex to caudate nucleus of the rat. *Exp Brain Res* 1975;23:203-210.
43. Gilman S, Carr D, Hollenberg J: Kinematic effects of deafferentation and cerebellar ablation. *Brain* 1976;99:311-330.
44. Dauth GW, Dafny N, Gilman S: Unit responses in hypothalamus and mesencephalic reticular formation to acoustic stimuli and electrical stimulation of ipsi- and contralateral amygdala. *Physiol Behav* 1976;17:621-629.
45. Hilal SK, Dauth GW, Burger LC, Gilman S: Effect of isotonic intrathecal water soluble contrast agents on electrically evoked cortico-spinal responses and segmental spinal reflexes in the cat. *Radiology* 1977;122:149-155.
46. Dauth GW, Defendini R, Gilman S, Tennyson VM, Kremzner LT: Long-term surface stimulation of the cerebellum in the monkey. I. Light microscopic, electrophysiologic, and clinical observations. *Surg Neurol* 1977;7:377-384.
47. Tennyson VM, Kremzner LT, Dauth GW, Defendini R, Gilman S: Long-term surface stimulation of the cerebellum in the monkey. II. Electron microscopic and biochemical observations. *Surg Neurol* 1977;8:17-29.
48. McKeough DM, Gilman S: Effects of basal ganglia lesions on muscle spindle activity. *Int J Neurol* 1977;12:73-85.
49. Abraham L, Copack PB, Gilman S: Brain stem pathways for vestibular projections to cerebral cortex in the cat. *Exp Neurol* 1977;55:436-448.

50. Dauth GW, Dell S, Gilman S: Alteration of Purkinje cell activity from transfolial stimulation of the cerebellum in the cat. *Neurology* 1978;28:654-660.
51. Hilal SK, Dauth GW, Hess KH, Gilman S: Development and evaluation of a new water soluble iodinated myelographic contrast medium with markedly reduced convulsive effects. *Radiology* 1978;126:417-422.
52. Salcman M, Defendini R, Correll J, Gilman S: Neuropathological changes in cerebellar biopsies of epileptic patients. *Ann Neurol* 1978;3:10-19.
53. Lechtenberg R, Gilman S: Speech disorders in cerebellar disease. *Ann Neurol* 1978;3:285-290.
54. Bromberg MB, Gilman S: Changes in rubral multiunit activity after lesions in the interpositus nucleus of the cat. *Brain Res* 1978;152:353-357.
55. Blum PS, Abraham LD, Gilman S: Vestibular, auditory, and somatic input to the posterior thalamus of the cat. *Exp Brain Res* 1979;34:1-9.
56. Blum PS, Gilman S: Vestibular, somatosensory, and auditory input to the thalamus of the cat. *Exp Neurol* 1979;65:343-354.
57. Blum PS, Day MJ, Carpenter MB, Gilman S: Thalamic components of the ascending vestibular system. *Exp Neurol* 1979;64:587-603.
58. Bryan RN, Dauth GW, Gilman S, Hilal SK: Effects of radiographic contrast agents on spinal cord physiology. *Investigative Radiology* 1981;16:234-239.
59. Kornhauser D, Bromberg MB, Gilman S: Effects of lesions of fastigial nucleus on static and dynamic responses of muscle spindle primary afferents in the cat. *J Neurophysiol* 1982;47:977-986.
60. Dauth GW, Yokoyama T, Gilman S: Responses of fastigial single neural units to transfolial electrical stimulation of the cerebellar cortex of the cat. *J Neural Trans Suppl* 1983;19:1-12.
61. Young AB, Penney JB, Dauth GW, Bromberg MB, Gilman S: Glutamate or aspartate as a possible neurotransmitter of cerebral corticofugal fibers in the monkey. *Neurology* 1983;33:1513-1516.
62. Dauth GW, Frey K, Gilman S: A densitometer for quantitative autoradiography. *J Neurosci Methods* 1983;9:243-251.
63. Gilman S, Dauth GW, Frey KA, Aldridge JW, Penney JB, Jr: Basal ganglia glucose metabolic and single neural unit activity in experimental hemiplegia. *Int J Neurol* 1984;18:79-93.
64. Dauth GW, Gilman S, Frey KA, Penney JB, Jr: Basal ganglia glucose utilization after recent precentral ablation in the monkey. *Ann Neurol* 1985;17:431-438.
65. Gebarski SS, Gabrielsen TO, Gilman S, Knake JE, Latack JT, Aisen AM: The initial diagnosis of multiple sclerosis: clinical impact of magnetic resonance scanning. *Ann Neurol* 1985;17:469-474.
66. Aldrich MS, Alessi AG, Beck RW, Gilman S: Cortical blindness: etiology, diagnosis, and prognosis. *Ann Neurol* 1987;21:149-158.
67. Foster NL, VanDerSpek AFL, Aldrich MS, Berent S, Hichwa RD, Sackellares JC, Gilman S, Agranoff BW: The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease as measured using positron emission tomography. *J Cereb Blood Flow Metab* 1987;7:415-420.
68. Gilman S, Dauth GW, Frey KA, Penney JB, Jr: Experimental hemiplegia in the monkey: Basal ganglia glucose metabolic activity during recovery. *Ann Neurol* 1987;22:370-376.

69. Abou-Khalil BW, Siegel GJ, Sackellares JC, Gilman S, Hichwa RD, Marshall R: Positron emission tomography studies of cerebral glucose metabolism in chronic partial epilepsy. *Ann Neurol* 1987;22:480-486.
70. Gilman S, Markel DS, Koeppe RA, Junck L, Kluin KJ, Gebarski SS, Hichwa RD: Cerebellar and brainstem hypometabolism in olivopontocerebellar atrophy detected with positron emission tomography. *Ann Neurol* 1988;23:223-230.
71. Levine SR, Twyman RE, Gilman S: The role of anticoagulation in cavernous sinus thrombosis. *Neurology* 1988;38:517-522.
72. Kluin KJ, Gilman S, Markel DS, Koeppe RA, Rosenthal G, Junck L: Speech disorders in olivopontocerebellar atrophy correlate with positron emission tomography findings. *Ann Neurol* 1988;23:547-554.
73. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA: Cerebral hypometabolism in progressive supranuclear palsy studied with PET. *Ann Neurol* 1988;24:399-406.
74. Rosenthal G, Gilman S, Koeppe RA, Kluin KJ, Markel DS, Junck L, Gebarski SS: Motor dysfunction in olivopontocerebellar atrophy is related to cerebral metabolic rate studied with positron emission tomography. *Ann Neurol* 1988;24:414-419.
75. Junck L, Gilman S, Rothley JR, Betley AT, Koeppe RA, Hichwa RD: A relationship between metabolism in frontal lobes and cerebellum in normal subjects studied with PET. *J Cereb Blood Flow Metab* 1988;8:774-782.
76. Shimoyama I, Dauth GW, Gilman S, Frey KA, Penney JB, Jr: Thalamic, brainstem and cerebellar glucose metabolism in the hemiplegic monkey. *Ann Neurol* 1988;24:718-726.
77. Aldridge JW, Gilman S, Levin I: A signal generator for testing extracellular recording amplifiers and probes. *Brain Res Bull* 1988;21:711-712.
78. Albin R, Aldridge JW, Young AB, Gilman S: Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity. *Brain Res* 1989;491:185-188.
79. Aldridge JW, Gilman S, Jones D: A microdrive positioning adapter for chronic single unit recording. *Physiol Behav* 1989;44:821-823.
80. Aldridge JW, Walden JL, Gilman S: Enhancing high-speed digitization of single-unit neuronal activity on a microcomputer using a hybrid software-hardware technique. *J Neurosci Meth* 1989;28:205-208.
81. Gilman S: Cerebellar diseases: studies with positron emission tomography. *Sem Neurol* 1989;9:370-376.
82. Sachdev RNS, Gilman S, Aldridge JW: Effects of excitotoxic striatal lesions on single unit activity in globus pallidus and entopeduncular nucleus of the cat. *Brain Res* 1989;501:295-306.
83. Albin RL, Gilman S: Parasagittal zonation of GABA-B receptors in molecular layer of rat cerebellar cortex. *Europ J Pharmacol* 1989;173:113-114.
84. Berent S, Giordani B, Gilman S, Junck L, Lehtinen S, Markel DS, Boivin M, Kluin KJ, Parks R, Koeppe RA: Neuropsychological changes in olivopontocerebellar atrophy. *Arch Neurol* 1990;47:997-1001.
85. Jaeger D, Gilman S, Aldridge JW: A multiwire microelectrode for single unit recording in deep brain structures. *J Neurosci Meth* 1990;32:143-148.
86. Aldridge JW, Gilman S, Dauth G: Spontaneous neuronal unit activity in the primate basal ganglia and the effects of precentral cerebral cortical ablation. *Brain Res* 1990;516:46-56.

87. Sackellares JC, Siegel GJ, Abou-Khalil BW, Hood TW, Gilman S, McKeever PE, Hichwa RD, Hutchins GD: Differences between lateral and mesial temporal metabolism interictally in epilepsy of mesial temporal origin. *Neurology* 1990;40:1420-1426.
88. Makowiec RL, Albin RL, Cha J-HJ, Young AB, Gilman S: Two types of quisqualate receptors are decreased in human olivopontocerebellar atrophy cerebellar cortex. *Brain Res* 1990;523:309-312.
89. Albin RL, Gilman S: Autoradiographic localization of inhibitory and excitatory amino acid neurotransmitter receptors in human normal and olivopontocerebellar atrophy cerebellar cortex. *Brain Res* 1990;522:37-45.
90. Bromberg MB, Junck L, Gebarski SS, McLean MJ, Gilman S: The Marinesco-Sjogren syndrome examined by computed tomography, magnetic resonance and ¹⁸F-2-fluoro-2-deoxy-D-glucose and positron emission tomography. *Arch Neurol* 1990;47:1239-1242.
91. Gilman S: Neurological complications of open heart surgery. *Ann Neurol* 1990;28:475-476.
92. Gilman S, Adams K, Koeppe RA, Berent S, Kluin KJ, Modell JG, Kroll P, Brunberg JA: Cerebellar and frontal hypometabolism in alcoholic cerebellar degeneration studied with positron emission tomography. *Ann Neurol* 1990;28:775-785.
93. Gilman S, Junck L, Markel DS, Koeppe RA, Kluin KJ: Cerebral glucose hypermetabolism in Friedreich's ataxia detected with positron emission tomography. *Ann Neurol* 1990;28:750-757.
94. Young AB, Dauth GW, Hollingsworth Z, Penney JB, Kaatz K, Gilman S: Quisqualate-sensitive and NMDA-sensitive [³H]glutamate binding in primate brain. *J Neurosci Res* 1990;27:512-521.
95. McDonald JW, Garofalo EA, Hood T, Sackellares JC, Gilman S, McKeever PE, Troncoso JC, Johnston MW: Altered excitatory and inhibitory amino acid receptor binding in hippocampus of patients with temporal lobe epilepsy. *Ann Neurol* 1991;29:529-541.
96. Aldridge JW, Gilman S: The temporal structure of spike trains in the primate basal ganglia: afferent regulation of bursting demonstrated with precentral cerebral cortical ablation. *Brain Res* 1991;542:123-138.
97. Sachdev RNS, Gilman S, Aldridge JW: Bursting properties of units in cat globus pallidus and entopeduncular nucleus: the effects of excitotoxic striatal lesions. *Brain Res* 1991;549:194-204.
98. Albin RL, Sakurai SY, Makowiec RL, Gilman S: Excitatory and inhibitory amino acid neurotransmitter binding sites in the cerebellar cortex of the pigeon (*Columba livia*). *J Chem Neuroanat* 1991;4:429-437.
99. Gilman S: Medical Progress: Advances in Neurology. Part 1. *New Engl J Med* 1992;326:1608-1616.
100. Gilman S: Medical Progress: Advances in Neurology. Part 2. *New Engl J Med* 1992;326:1671-1676.
101. Foster NL, Gilman S, Berent S, D'Amato C, Koeppe RA, Hicks SP: Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. *J Neurol Neurosurg Psychiatr* 1992;55:707-713.
102. Albin RL, Gilman S: GABA_A, GABA_B, and benzodiazepine binding sites in the cerebellar cortex of the red-eared turtle (*Pseudemys scripta*). *Brain Res* 1992;595:164-166.

103. Shope JT, Holmes SB, Sharpe PA, Goodman C, Izenson S, Gilman S: Planning for a statewide network of dementia assessment services: a survey of geriatric assessment services in Michigan. *Am J Alzheimer's Care and Research and Related Disorders and Research* 1992;7:31-36.
104. Albin RA, Hollingsworth Z, Sakurai S, Dauth GW, Gilman S: Inhibitory and excitatory amino acid neurotransmitter binding sites in cynomolgus monkey (*Macaca fascicularis*) spinal cord. *Brain Res* 1993; 604:354-357.
105. Kluin KJ, Foster NL, Berent S, Gilman S: Perceptual analysis of speech disorders in progressive supranuclear palsy. *Neurology* 1993; 43:563-566.
106. Adams KM, Gilman S, Koeppe RA, Kluin KJ, Brunberg JA, Dede D, Berent, Kroll PD: Neuropsychological deficits are correlated with frontal hypometabolism in positron emission tomography studies of older alcoholic patients. *Alcohol Clin Exp Res* 1993; 17:205-210.
107. Shope JT, Holmes SB, Hogan J, Tang G, Izenson S, Gilman S, Jones MZ: Pathologists' participation in postmortem examinations for patients with dementia. *The Gerontologist* 1993; 33:461-467.
108. Jaeger D, Gilman S, Aldridge JW: Primate basal ganglia activity in a precued reaching task - preparation for movement. *Exp Brain Res* 1993; 95:51-64.
109. Shope JT, Holmes SB, Sharpe PA, Goodman C, Izenson S, Gilman S, Foster NL: Services for persons with dementia and their families: a survey of information and referral agencies in Michigan. *The Gerontologist* 1993; 33:529-533.
110. Henry TR, Frey KA, Sackellares JC, Gilman S, Koeppe RA, Brunberg JA, Ross DA, Berent S, Young AB, Kuhl DE: In vivo cerebral metabolism and central benzodiazepine receptor binding in temporal lobe epilepsy. *Neurology* 1993; 43:1998-2006.
111. Gilman S: Cerebellar control of movement. *Ann Neurol* 1994; 35:3-4.
112. Junck L, Gilman S, Gebarski SS, Koeppe RA, Kluin KJ, Markel DS: Structural and functional brain imaging in Friedreich's ataxia. *Arch Neurol* 1994; 51:349-355.
113. Vilensky JA, Gilman S, Dec EM: The Denny-Brown collection: a research and teaching resource. *Ann Neurol* 1994; 36:247-251.
114. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St. Laurent RT: Patterns of cerebral glucose metabolism detected with PET differ in multiple system atrophy and olivopontocerebellar atrophy. *Ann Neurol* 1994; 36:166-175.
115. Connell CM, Kole SL, Benedict CJ, Holmes SB, Gilman S, Beane GE: Increasing coordination of the dementia service delivery network: Planning for the Community Outreach Education Program. *The Gerontologist* 1994;34:700-706.
116. Adams KM, Gilman S, Koeppe R, Kluin K, Junck L, Lohman M, Johnson-Greene D, Berent S, Dede D, Kroll P: Correlation of neuropsychological function with cerebral metabolic rate in subdivisions of the frontal lobes of older alcoholic patients measured with [¹⁸F]fluorodeoxyglucose and positron emission tomography. *Neuropsychology* 1995;9:275-280.
117. Gilman S, St. Laurent RT, Koeppe RA, Junck L, Kluin KJ, Lohman M: A comparison of cerebral blood flow and glucose metabolism in olivopontocerebellar atrophy using PET. *Neurology* 1995;45:1345-1352.
118. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St. Laurent RT: Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography. *Ann Neurol* 1995;38:176-185.

119. Jaeger D, Gilman S, Aldridge JW: Neuronal activity in the striatum and pallidum of primates related to the execution of externally cued reaching movements. *Brain Res* 1995;694:111-127.
120. Gilman S, Sima AF, Junck L, Kluin KJ, Koeppe RA, Lohman M, Little R: Spinocerebellar ataxia type 1 with multiple system degeneration and glial cytoplasmic inclusions. *Ann Neurol* 1996; 39:241-255.
121. Vilensky JA, Gilman S, Morecraft RJ. DC 60: An example of one of the 450 cases that comprise the Denny-Brown collection of primate lesion material. *Movement Disorders* 1996; 11:207-213.
122. Gilman S, Quinn NP: The relationship of multiple system atrophy to sporadic olivopontocerebellar atrophy and other forms of idiopathic late onset cerebellar atrophy. *Neurology* 1996; 46:1197-1199.
123. Connell CM, Kole SL, Avey H, Benedict CJ, Gilman S: Attitudes about Alzheimer's disease and the dementia service delivery network among family caregivers and service providers in rural Michigan. *Am J Alz Dis* 1996; 11:15-25.
124. Kluin KJ, Gilman S, Lohman M, Junck L. Characteristics of the dysarthria of multiple system atrophy. *Arch Neurol* 1996; 53:545-548.
125. Berent S, Giordani B, Gilman S, Junck L, Kluin KJ, Koeppe RA. Psychological factors and PET measured glucose metabolism in olivopontocerebellar atrophy. *Assessment* 1996; 3:335-351.
126. Vilensky JA, Gilman S: The Denny-Brown collection: useful resource for physical therapy practitioners and educators. *Physical Therapy* 1996; 76:890-893.
127. Gilman S, Koeppe RA, Adams K, Johnson-Greene D, Junck L, Kluin KJ, Brunberg J, Martorello S, Lohman M. Positron emission tomography studies of cerebral benzodiazepine-receptor binding in chronic alcoholics. *Ann Neurol* 1996; 40:163-171.
128. Gilman S, Adams KM, Johnson-Greene D, Koeppe RA, Junck L, Kluin K, Martorello S, Heumann M, Hill E: Effects of disulfiram on positron emission tomography and neuropsychological studies in severe chronic alcoholism. *Alcohol Clin Exp Res* 1996; 8:1456-1461.
129. Vilensky JA, Gilman S: Utilization of available films and records of primates with central nervous system lesions. *Folia Primatol* 1996; 66:204-208.
130. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RA, Gilman S, Kuhl DE. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. *Ann Neurol* 1996; 40:873-884.
131. Gilman S, Frey KA, Koeppe RA, Junck L, Little R, Vander Borght TM, Lohman M, Martorello S, Lee LC, Jewett DM, Kilbourn MR. Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography. *Ann Neurol* 1996; 40: 885-892.
132. Gilman S: Alzheimer's disease. *Perspectives in Biology and Medicine* 1997; 40:230-245.
133. Gilman, S, Vilensky JA: How Denny-Brown came to Harvard. *Harvard Medical Alumni Bulletin* 1997; 70:46-50.
134. Vilensky JA, Gilman S, Dunn EA, Wilson WJ. Utilization of the Denny-Brown Collection: differential recovery of forelimb and hind limb stepping after extensive unilateral cerebral lesions. *Behav Brain Res* 1997; 82:223-233.

135. Johnson-Greene D, Adams KM, Gilman S, Kluin K, Junck L, Martorello S, Heumann M: Impaired upper limb coordination in alcoholic cerebellar degeneration. *Arch Neurol* 1997; 54:436-439.
136. Aldridge JW, Thompson JF, Gilman S: Unilateral striatal lesions in the cat disrupt well-learned motor plans in a go/no-go reaching task. *Exp Brain Res* 1997; 113:379-393.
137. Foster NL, Wilhelmsen K, Sima AAF, Jones MZ, D'Amato CJ, Gilman S, and Conference Participants: Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. *Ann Neurol* 1997; 41:706-715.
138. Johnson-Greene D, Adams KM, Gilman S, Koeppe RA, Junck L, Kluin K, Martorello S, Heumann M, Hill E: Effects of abstinence and relapse upon neuropsychological function and cerebral glucose metabolism in severe chronic alcoholism. *J Clin Exp Neuropsych* 1997; 19:378-385.
139. Antuono P, Doody R, Gilman S, Huff J, Scheltens P, Ueda K, Khachaturian ZS: Diagnostic criteria for dementia in clinical trials: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. *Alzheimer Dis Ass Disord* 1997; 11S3:22-25.
140. Homma A, Brodaty H, Bruno G, Cummings JL, Gilman S, Gracon S, McKeith IG: Clinical trials of treatment for noncognitive symptoms of dementia: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. *Alzheimer Dis Ass Disord* 1997; 11S3:54-56.
141. Vilensky JA, Gilman S: Positive and negative factors in movement control: a current review of Denny-Brown's hypothesis. *J Neurol Sci* 1997;151:149-158.
142. Gilman S: Imaging the brain. First of two parts. *N Engl J Med* 1998;338:812-820.
143. Gilman S: Imaging the brain. Second of two parts. *N Engl J Med* 1998;338:889-896.
144. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group: Consensus report of the working group on: "Molecular and Biochemical Markers of Alzheimer's Disease". *Neurobiol Aging* 1998;19:109-116.
145. Adams KM, Gilman S, Johnson-Greene D, Koeppe RA, Junck L, Kluin KJ, Martorello S, Johnson M, Heumann M, Hill E: The significance of family history status in relation to neuropsychological test performance and cerebral glucose metabolism studied with positron emission tomography in older alcoholic patients. *Alcohol Clin Exp Res* 1998;22:105-110.
146. Vilensky JA, Gilman S, Dunn E: Derek E. Denny-Brown (1901-1981): His life and influence on American neurology. *J Med Biography* 1998;6:73-78.
147. Gilman S, Koeppe RA, Adams KM, Junck L, Kluin KJ, Johnson-Greene D, Martorello S, Heumann M, Bandekar R: Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[¹¹C]dihydrotetrabenazine and positron emission tomography. *Ann Neurol* 1998;44:326-333.
148. Vilensky JA, Morecraft RJ, Gilman S, Cook JA: "Mouth-feeding" in monkeys after sensorimotor system lesions: an analysis based upon the Denny-Brown collection. *Behavioral Brain Res* 1998;94:311-315.
149. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK. Consensus statement on the diagnosis of multiple system atrophy. *J*

- Autonomic Nervous System 1998;74:189-192; Clinical Autonomic Research 1998;8:359-362; J Neurol Sci 1999;163:94-98.
150. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson's disease. Arch Neurol 1999;56:33-39.
 151. Vilensky JA, Barnhart SW, Gilman S, Cook JA, Morecraft RJ: Disorders of proprioceptive responses in monkeys after cerebellar lesions: an analysis using the Denny-Brown collection. J Neurol Sci 1999;163:111-118.
 152. Gilman S, Koeppe RA, Junck L, Little R, Kluin KJ, Heumann M, Martorello S, Johanns J: Decreased striatal monoaminergic terminals in multiple system atrophy detected with PET. Ann Neurol 1999;45:769-777.
 153. Gilman S, Vilensky JA, Morecraft RW, Cook JA: Denny-Brown's views on the pathophysiology of dystonia. J Neurol Sci 1999;167:142-147.
 154. Dickson DW, Liu W, Hardy J, Farrer M, Mehta N, Uitti R, Mark M, Zimmerman T, Golbe L, Sage J, Sima A, D'Amato C, Albin R, Gilman S, Yen S: Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 1999;155:1241-1251.
 155. Foster NL, Minoshima S, Johanns J, Little R, Heumann ML, Kuhl DE, Gilman S: PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 2000;54:1768-1773.
 156. Evidente VGH, Gwinn-Hardy KA, Caviness JN, Gilman S: Hereditary ataxias. Mayo Clinic Proc 2000;75:475-490.
 157. Gilman S, Little R, Johanns J, Heumann M, Kluin KJ, Junck L, Koeppe RA, An H: Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy. Neurology 2000;55:527-532.
 158. Gilman S: The spinocerebellar ataxias. Clin Neuropharmacol 2000;23:296-303.
 159. Vilensky JA, Gilman S: Integrating the work of D. Denny-Brown and some of his contemporaries into current studies of the primate motor cortex. J Neurol Sci 2001;182:83-87.
 160. Gilman S: Biochemical changes in multiple system atrophy detected with positron emission tomography. Parkinsonism and Related Disorders 2001;7:253-256.
 161. Vilensky JA, Gilman S: Sensory disturbances after focal extirpations of the human "motor" cortex. Motor Control 2001;3:222-230.
 162. Kluin KJ, Gilman S, Foster NL, Sima AAF, D'Amato CJ, Bruch LA, Bluemlein L, Little R, Johanns J: Neuropathologic correlates of dysarthria in progressive supranuclear palsy. Arch Neurol 2001;58:265-269.
 163. Vilensky JA, Gilman S. Neurognostics Question 16: the size principle. J Hist Neurosci 2002;11:180 and 183-184.
 164. Zannolli R, Gilman S, Bernini A, Galluzzi P, Rossi S, Galimberti D, Pucci L, D'Ambrosio A, Morgese G, Giannini F. Familial autonomic failure with cerebellar degeneration. Arch Neurol 2002;59:1319-1326.
 165. Vilensky JA, Robertson WM, Gilman S. Denny-Brown, Wilson's disease and BAL (British antilewisite [2, 3-dimercaptopropanol]) Neurology 2002;59:914-916.
 166. Gilman S. Joint position sense and vibration sense: anatomical organisation and assessment. J Neurol Neurosurg Psychiatry 2002;73:473-477.
 167. Vilensky JA, Gilman S. Motor cortex extirpation (1886-1950): the influence of Sir Victor Horsley. Neurosurgery 2002;51:1484-1488.

168. Johnson-Greene D, Adams KM, Gilman S, Junck L. Relationship between neuropsychological function and emotional distress in severe chronic alcoholism. *The Clin Neuropsychol* 2002;16:300-309.
169. Vilensky JA, Gilman S. Lesions of the precentral gyrus in nonhuman primates: a premedline bibliography. *Int J Primatol* 2002;23:1319-1333.
170. Berent S, Giordani B, Gilman S, Trask CL, Little RJA, Johanns JR, Junck L, Kluin KJ, Heumann M, Koeppe RA. Patterns of neuropsychological performance in multiple system atrophy compared to sporadic and hereditary olivopontocerebellar atrophy. *Brain and Cognition* 2003;50:194-206.
171. Vilensky JA, Gilman S. Horsley was the first to use electrical stimulation of the human cerebral cortex operatively. *Surg Neurol* 2003;58:425-426.
172. Gilman S, Koeppe RA, Chervin R, Consens F, Little R, An H, Junck L, Heumann M. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. *Neurology* 2003;61:29-34.
173. Gilman S, Koeppe RA, Chervin R, Consens F, Little R, An H, Junck L, Heumann M. Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA. *Neurology* 2003;61:35-39.
174. Vilensky JA, Gilman S. Using extirpations to understand the human motor cortex. Horsley, Foerster, and Bucy. *Arch Neurol* 2003;60:446-451.
175. Orgogozo J-M, Gilman S, Dartigues J-F, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after A β 42 immunization. *Neurology* 2003;61:46-54.
176. Vilensky JA, Stone JL, Gilman S. Feud and fable: the Sherrington-Horsley polemic and the delayed publication. *J Hist Neurosci* 2003;12:368-375.
177. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, Persad C, Heumann M, Wernette K. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. *Ann Neurol* 2004;55:774-780.
178. Vilensky JA, Bell DR, Gilman S. "On the Physiology of Micturition" by Denny-Brown and Robertson: a classic paper revisited. *Urology* 2004;64:182-186.
179. Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhelef F, Ghorayeb I, Ory F, Galitzky M, Scaravilli T, Bozi M, Colosimo C, Gilman S, Shults CW, Quinn NP, Rascol O, Poewe W, and the European MSA Study Group. Development and validation of the unified multiple system atrophy rating scale (UMSARS). *Mov Disord* 2004;19:1391-1402.
180. Vilensky JA, Bell DR, Gilman S. "An investigation of the nervous control of defecation" by Denny-Brown and Robertson: a classic paper revisited. *Colorectal Disease* 2004;6:376-383.
181. Vilensky JA, Gilman S, Sinish P. Denny-Brown, Boston City Hospital and the history of American neurology. *Perspect Biol Med* 2004;47:505-518.
182. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, Persad C, Heumann M, Wernette K. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing [18 F]fluorodeoxyglucose and neuropsychological testing. *Exp Neurol* 2005;191:S95-S103.
183. Vilensky JA, Gilman S, Casey K. Sir Victor Horsley, Mr. John Marshall, the nervi nervorum and pain: more than a century ahead of its time. *Arch Neurol* 2005;62:499-501.

184. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Boada Rovira M, Forette F, Orgogozo J-M. Clinical effects of A-beta immunization (AN1792) in patients with AD in an interrupted trial. *Neurology* 2005;64:1553-1562.
185. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Effects of A-beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. *Neurology* 2005;64:1563-1572.
186. Consens FB, Chervin RD, Koeppe RA, Little R, Liu S, Junck L, Angell K, Heumann M, Gilman S. Validation of a polysomnographic score for REM sleep behavior disorder (RBD). *Sleep* 2005;28:993-997.
187. Vilensky JA, Sinish PR, Stone JL, Gilman S. The publications of Sir Victor Horsley: a listing and an assessment. *Neurosurgery*. 2005;57:581-584.
188. Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, Masliah E, Low P, Sandroni P, Trojanowski JQ, Ozelius L, Foroud T. The North American multiple system atrophy study group. *J Neural Transm* 2005 Dec;112:1687-1694.
189. Colosimo C, Gilman S, Quinn N, Wenning GK. Preface - Special issue: Multiple system atrophy. *J Neural Transm* 2005;112:1601-1603.
190. Gilman S. Functional imaging with positron emission tomography in multiple system atrophy. *J Neural Transm* 2005;112:1647-1655.
191. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, Frey KA, Albin RL. ¹¹C-DTBZ and ¹⁸F-FDG PET measures in differentiating dementias. *J Nucl Med* 2005;46:936-944.
192. Vilensky JA, Goetz C, Gilman S. Movement disorders associated with encephalitis lethargica: A video compilation. *Mov Disord* 2006;21:1-8.
193. Zipes DP, Zvaifler NJ, Glasscock RJ, Gilman S, Muñoz A, Gogolak V, Gordis L, Dedon PC, Guengerich FP, Wasserman SI, Witztum JL, Wogan GN. Analysis of the efficacy and safety of Rosuvastatin: an independent analysis of risks and benefits. *Medscape General Medicine* 2006;8:73 available at <http://medgenmed.medscape.com/viewarticle/533930>.
194. Gilman S. Pharmacologic management of ischemic stroke: relevance to stem cell therapy. *Exp Neurol* 2006;199:28-36.
195. Gilman S. Time course and outcome of recovery from stroke: relevance to stem cell treatment. *Exp Neurol* 2006;199:37-41.
196. Raffel DM, Koeppe RA, Little R, Wang C-N, Liu S, Junck L, Heumann M, Gilman S. PET measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes. *J Nucl Med* 2006;47:1-9.
197. Zhukareva V, Joyce S, Schuck T, Van Deelin V, Hurtig H, Albin R, Gilman S, Chin S, Miller B, Trojanowski JQ, Lee VM-Y. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter. *Ann Neurol* 2006;60:335-345.
198. Vilensky JA, Gilman S. Encephalitis lethargica: could this disease be recognized if the epidemic recurred? *Prac Neurol* 2006;6:360-367.
199. Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, Reich S, Colcher A, Stern MB, Ondo WG, Jankovic J, Huang N, Tanner CM, Novak P, Gilman S, Marshall FJ, Wooten GF, Chelimsky TC, Shults CW, and the North American Multiple System Atrophy Study Group. The G2019S mutation in the leucine rich repeat kinase 2 gene is not associated with multiple system atrophy. *Mov Disord* 2007;22(4):546-549.

200. Vilensky JA, Foley P, Gilman S. Children and encephalitis lethargica. *Pediatric Neurology* 2007;37(2):79-84.
201. May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, MD, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW, and the North American Multiple System Atrophy Study Group. Potential outcome measures and trial design issues for multiple system atrophy. *Mov Disord* 2007;22(16):2371-2377.
202. Burns JW, Consens FB, Little RJ, Angell KJ, Gilman S, Chervin RD. EMG variance during polysomnography as an assessment for REM sleep behavior disorder. *Sleep* 2007;30(12):1771-1778.
203. Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA. Differentiating Alzheimer disease from dementia with Lewy bodies and Parkinson disease with [¹¹C]DTBZ PET. *Alzheimer's & Dementia* 2008;4(1) (Suppl 1):S67-S76.
204. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JCS, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium. *Alzheimer's & Dementia* 2008;4(3):156-163. PMID: PMC2544623
205. Vilensky JA, Mukhamedzyanov RZ, Gilman S. Encephalitis lethargica in the Soviet Union. *Eur Neurol* 2008;60:113-121.
206. McCall S, Vilensky JA, Gilman S, Taubenberger JK. The relationship between encephalitis lethargica and influenza: A critical analysis. *J Neurovirol* 2008;14(3):177-185.
207. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood N, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology* 2008;71:670-676.
208. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Phelps C, Roses A, Simpkins JW, Schneider LS, Chair, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Buckholtz N, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. *Alzheimer's & Dementia* 2009;5:83-92.
209. Lipp A, Sandroni P, Ahlskog JE, Fealey RD, Kimpinski K, Iodice V, Gehrking TL, Weigand SD, Sletten DM, Gehrking JA, Nickander KK, Singer W, Maraganore DM, Gilman S, Wenning GK, Shults CM, Low PA. Prospective differentiation of multiple system atrophy from Parkinson's disease with and without autonomic failure. *Arch Neurol* 2009;66(6):742-750. PMID: 19506134

210. Knight EM, Gilman S, Selwa L. Status epilepticus in Wilson's disease. *Epileptic Disord.* 2009 Jun;11(2):138-43. Epub 2009 May 27. PMID: 19473947
211. Salloway S, Sperling R, Gilman S, Fox N, Blennow K, Raskind M, Sabbagh M, Honig L, Doody R, van Dyck C, Mulnard R, Mulnard R, Gregg K, Liu E, Lieberburg I, Schenk D, Black R, Grundman M for the Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer's disease *Neurology* 2009;73:1-10. PMID: 19923550
212. Van Deerlin VM, ↯ Gilman S, ↯ Lee VM-Y. Common genetic variants at 7p21 show strong association with frontotemporal lobar degeneration with TDP-43 inclusions. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nat Genet* 2010 Mar;42(3):234-9. Epub 2010 Feb 14. PMID: 20154673.
213. Albin RL, Koeppe RA, Burke JF, Giordani B, Kilbourn MR, Gilman S, Frey KA. Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [¹¹C]dihydrotrabenazine-PET in evaluation of early dementia and mild cognitive impairment. *Arch Neurol* 2010;67(4):440-446. PMID: 20385910.
214. Gilman S, Koeppe RA, Nan B, Wang C-N, Wang X, Junck L, Chervin R, Consens F, Bhaumik A. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes *Neurology* 2010;74:1416–1423.
215. Vilensky JA, Gilman S, McCall S. A historical analysis of the relationship between encephalitis lethargic and postencephalitic parkinsonism: a complex rather than a direct relationship. *Mov Disord* 2010;25(9):1116-1123.
216. Vilensky JA, Gilman S, McCall S. Does the historical literature on encephalitis lethargica support a simple (direct) relationship with postencephalitic parkinsonism? *Mov Disord* 2010;25(9):1124-1130.
217. Geser F, Malunda JA, Hurtig HI, Duda JE, Wenning GK, Gilman S, Low PA, Lee VM, Trojanowski JQ. Subcortical TDP-43 pathology occurs infrequently in multiple system atrophy. *Neuropathol Appl Neurobiol* 2010 Oct 13. doi: 10.1111/j.1365-2990.2010.01136.x. [Epub ahead of print] PMID: 20942898

Articles Accepted for Publication

1. Iodice V, Lipp A, Ahlskog JE, Sandroni P, Fealey RD, Parisi JE, Matsumoto JY, Maraganore DM, Benarroch EE, Kimpinski K, Singer W, Gehrking TL, Gehrking JA, Sletten DM, Schmeichel AM, Bower JH, M.D, Gilman S, Figueroa J, A. Low PA. Autopsy confirmed multiple system atrophy: Mayo experience and role of autonomic function tests. *Arch Neurol* (In Press) 2010.

Articles Submitted for Publication

1. Jun G, ↯ Gilman S, ↯ Schellenberg GD. Meta-Analysis confirms CR1, CLU, and PICALM as Alzheimer's disease risk loci and reveals interactions with APOE genotypes. (Submitted) 2010.
2. Naj AC, ↯ Alzheimer's Disease Genetics Consortium, ↯ Schellenberg GD. Genome-wide Association Study of Late-Onset Alzheimer Disease identifies disease associated variants in MS4A4/MS4A6E, CD2AP, CD33, and EPHA1. (Submitted) 2010.

3. Gilman S, Koeppe RA, Nan B, Wang C-N, Wang X, Junck L, Chervin R, Consens F, Bhaumik A. Differences in dopaminergic projections between cerebellar and parkinsonian forms of multiple system atrophy. (Submitted) 2010.
4. Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, Frey KA. Assessment of mld dementia with [11C]DTBZ and [11C]PiB positron emission tomography. (Submitted) 2010.
5. Salloway S, Sperling R, Keren R, Porseteinsson A, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Pastrak A, Cedarbaum J for the ELND005-AD201 Investigators. Phase 2 safety and efficacy study of ELND005 (scyllo-inositol) in mild-moderate Alzheimer's disease. (Submitted) 2010.
6. Vilensky JA, Duvoisin RC, Gilman S. The diagnosis of postencephalitic parkinsonism at the Neurological Unit of Boston City Hospital, 1930-1981. (Submitted) 2010.

Non Peer Reviewed

1. Gilman S: The diagnosis of multiple sclerosis. J Amer Med Assoc 1981;246:1122-1123.
2. Gilman S: D. Denny-Brown. Neurology 1982;32:1-6.
3. Gilman S: Russell N. DeJong. Ann Neurol 1990;29:108-109.
4. Vilensky JA, Gilman S: The Denny-Brown Collection. Neurology 1990;40:1636.
5. Gilman S: Michael S. Aldrich, M.D. (1949-2000). Neurology 2001;56:6-7.
6. Gilman S. Foreword. In: Manto MU, Pandolfo , Eds, *The Cerebellum and Its Disorders*. Cambridge, Cambridge University Press, 2001.
7. Gilman S. Editorial. A Tribute to John R. Sladek, Jr. Exp Neurol 2003;179:1-3.
8. Gilman S. Editorial. New directions for Experimental Neurology. Exp Neurol 2003;179:4-5.
9. Gilman S. Editorial. Exp Neurol 2005;191:1.
10. Gilman S. Editorial. Exp Neurol 2005;196:209.
11. Gilman S. Editorial. Thanks to Moses Chao and welcome to Sally Temple. Exp Neurol 2006;199:237.
12. Gilman S. Editorial. Progress at Experimental Neurology. Exp Neurol 2008;209:1-2.
13. Gilman S. Foreword. In: Baloh RW, Kerber KA, *Clinical Neurophysiology of the Vestibular System*. New York, Oxford University Press, 2011.

Chapters in Books

1. Gernandt BE, Gilman S: Generation of labyrinthine impulses, descending vestibular pathways, and modulation of vestibular activity by proprioceptive, cerebellar, and reticular influences. In: Rassmussen GL, Windle WF, Eds, *Neural Mechanisms of the Auditory and Vestibular Systems*. Springfield:Charles C Thomas 1961;324-348.
2. Van Der Meulen JP, Gilman S, Denny-Brown D: Muscle spindle activity in animals with chronic lesions of the central nervous system. In: Granit R, Ed, *1st Nobel Symposium: Muscular Afferents and Motor Control*. Stockholm:Almqvist and Wiksell 1966;139-149.
3. Gilman S: Differential cerebellar regulation of muscle stretch receptor sensitivity. In: Locke S, Ed, *Modern Neurology. Papers in Tribute to D. Denny-Brown*. Boston:Little-Brown Co. 1969;149-159.

4. Gilman S: The nature of cerebellar dyssynergia. In: Williams D, Ed, *Modern Trends in Neurology*. London:Butterworths 1970;5:60-79.
5. Copack P, Dafny N, Gilman S: Neurophysiological evidence of vestibular projections to thalamus, basal ganglia and cerebral cortex. In: Frigyesi TL, Rinvik E, Yahr M, Eds, *Corticothalamic projections and sensorimotor activities*. New York:Raven Press 1972;309-339.
6. Gilman S, Copack P, Lieberman JS: Gamma and alpha motoneuron responses in experimental hypertonia. In: *Functional Neuromuscular Stimulation*. Washington, DC:National Academy of Sciences 1972;93-99.
7. Gilman S: Significance of muscle receptor control systems in the pathophysiology of experimental postural abnormalities. In: Desmedt JE, Ed, *New Developments in Electromyography and Clinical Neurophysiology*. Basel:Karger 1973;3:175-193.
8. Cooper IS, Gilman S: Chronic stimulation of the cerebellar cortex in the therapy of epilepsy in the human. In: Field WS, Ed, *Neural Organization and Its Relevance to Prosthetics*. New York:Intercontinental Book Corp 1973;371-375.
9. Gilman S: A cerebello-thalamo-cortical pathway controlling fusimotor activity. In: Stein RB, Pearson KG, Smith RS, Redford JB, Eds, *Control of Posture and Locomotion*. New York:Plenum Press 1973;309-329.
10. Gilman S: Cerebellar, thalamic and cerebral control of proprioceptive responses in relation to Parkinson's disease. In: Siegfried J, Ed, *Parkinson's Disease. Rigidity, Akinesia, Behavior*. Bern:Hans Huber 1973;2:47-58.
11. Dauth G, Carr D, Gilman S: Cerebellar cortical stimulation effects on EEG activity and seizure after-discharge in anesthetized cats. In: Cooper IS, Riklan M, Snider RS, Eds, *The Cerebellum, Epilepsy, and Behavior*. New York:Plenum Press 1974;229-244.
12. Cooper IS, Amin I, Gilman S, Waltz JM: The effect of chronic stimulation of cerebellar cortex on epilepsy in man. In: Cooper IS, Riklan M, Snider RS, Eds, *The Cerebellum, Epilepsy, and Behavior*. New York:Plenum Press 1974;119-171
13. Gilman S: Primate models of postural abnormalities. In: Meldrum BS, Marsden CD, Eds, *Primate Models of Neurological Disorders*. New York:Raven Press 1975;10:55-76.
14. Gilman S, Romanul FCA: Hereditary dystonic paraplegia with amyotrophy and mental deficiency: Clinical and neuropathological characteristics. In: Vinken PJ, Bruyn GW, Eds, *Handbook of Clinical Neurology*. Amsterdam:North-Holland Publishing Co. 1975;22:445-465.
15. Gilman S: Patterns of motoneuron responses to natural stimuli. In: Desiraju T, Ed, *Mechanisms in Transmission of Signals for Conscious Behavior*. Amsterdam:Elsevier 1976;22-43.
16. Gilman S, Dauth GW, Tennyson VM, Kremzner LT, Defendini R, Correll JW: Clinical, morphological, biochemical, and physiological effects of cerebellar stimulation In: Hambrecht FT, Reswick JB, Eds, *Functional Electrical Stimulation*. New York:Marcel Dekker 1977;191-226.
17. Gilman S: The cerebellum. In: Wolman BB, Ed, *International Encyclopedia of Neurology, Psychiatry, Psychoanalysis, and Psychology*. Van Nostrand:Reinhold 1977.
18. Gilman S: Gait disorders. In: Rowland LP, Ed, *Merritt's Textbook of Neurology*. Philadelphia:Lea and Febiger 1984;44-48.
19. Gilman S: Parenchymatous cerebellar degeneration. In: Rowland LP, Ed, *Merritt's Textbook of Neurology*. Philadelphia:Lea and Febiger 1984;506-508.

20. Gilman S, Kluin K: Perceptual analysis of speech disorders in Friedreich disease and olivopontocerebellar atrophy. In: Bloedel JR, Dichgans J, Eds, *Cerebellar Functions*. Berlin:Springer Verlag 1984;148-163.
21. Gilman S, Dauth GW, Aldridge JW, Frey KA, Penney JB, Jr: Changes in basal ganglia metabolic and neural unit activity after motor cortex ablation. In: Uemara K, Ed, *Proceedings of the 5th Annual Meeting of the Japanese Congress of Neurological Surgeons*. Jap Congr Neurol Surg:Tokyo 1985;161-168.
22. Gilman S: The cerebellum: Its role in posture and movement. In: Swash M, Kennard C, Eds, *Scientific Basis of Clinical Neurology*. Edinburgh:Churchill Livingstone 1985;36-55.
23. Gilman S: Cerebellar deficit. In: Asbury AK, McKhann GM, McDonald WI, Eds, *Diseases of the Nervous System*. Philadelphia:Saunders 1986;401-422.
24. Gilman S: Inherited ataxia. In: Johnson RT, Ed, *Current Therapy in Neurologic Disease - 2*. Toronto:Decker 1987;224-232.
25. Gilman S, Markel D, Koeppel RA, Junck L, Hichwa RD: Olivopontocerebellar atrophy studied with positron emission tomography In: Daroff R, Conomy J, Eds, *Contributions to Contemporary Neurology*. Stoneham:Butterworths 1988.
26. Gilman S, Junck L, Young AB, Hichwa RD, Markel DS, Koeppel RA, Ehrenkaufer RE: Cerebral metabolic activity in idiopathic dystonia studied with positron emission tomography. In: Fahn S, Marsden CD, Calne DB, Eds, *Dystonia 2*. Advances in Neurology, Volume 50. New York:Raven Press 1988.
27. Gilman S: Functional localization in the cerebellum, Parts 1 and 2. In: Scheinberg P, Ed, *Neurology and Neurosurgery Update Series, Volume 7*. Princeton:Continuing Professional Education Center, Inc. 1988;Lessons 35 and 36.
28. Young AB, Penney JB, Hollingsworth Z, Bromberg M, Dauth G, Gilman S: Excitatory amino acids and their receptors in motor pathways. In: Cavalheiro EA, Lehmann J, Turdki L, Eds, *Frontiers in Excitatory Amino Acid Research*. New York:Alan R. Liss 1988;371-376.
29. Gilman S, Fitzgerald F: Nervous System. In: Judge RD, Zuidema GD, Fitzgerald FT, Eds, *Clinical Diagnosis, Fifth Edition*. Boston:Little, Brown and Co. 1989.
30. Gilman S: Olivopontocerebellar atrophy. In: Martin WRW, Ed, *Functional Imaging in Movement Disorders*. Boca Raton:CRC Press 1990;157-176.
31. Albin RL, Young AB, Penney JB, Makowiec RL, Gilman S: Chemical neuroanatomy and in vitro receptor autoradiography: a basis for cerebral positron emission tomography. In: Kuhl D, Ed, *In Vivo Imaging of Neurotransmitter Functions in Brain, Heart and Tumors*. Washington, DC:American College of Nuclear Physicians 1991;29-44.
32. Aldridge JW, Jaeger D, Gilman S: A comparison of single unit activity in primate caudate nucleus and putamen in a sensory cued motor task. In: Bernardi G, Carpenter MB, DiChiara G, Eds, *Basal Ganglia III*. New York:Plenum Press 1991;303-310.
33. Gilman S: Positron emission tomography studies of the cerebellar degenerations. In: Plaitakis A, Ed, *Cerebellar Degenerations: Clinical Neurobiology*. Norwell:Kluwer Academic Publishers 1992;443-459.
34. Gilman S, Gebarski SS: Cerebellar disorders. In: Mazziotta JC, Gilman S, Eds, *Clinical Brain Imaging: Principles and Applications*. Philadelphia:F.A. Davis 1992; 370-410.

35. Mazziotta JC, Gilman S: Epilogue: future visions. In: Mazziotta JC, Gilman S, Eds, *Clinical Brain Imaging: Principles and Applications*. Philadelphia:F.A. Davis Co. 1992;458-468.
36. Gilman S, Kluin KJ: Speech disorders in cerebellar degeneration studied with positron emission tomography. In: Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KS, Eds, *Neurological Disorders of the Larynx*. New York:Thieme Medical Publishers, Inc. 1992;279-285.
37. Gilman S: Cerebellum and motor dysfunction. In: Asbury AK, McKhann GM, McDonald WI, Eds, *Diseases of the Nervous System: Clinical Neurobiology, edition 2*. Philadelphia:Saunders 1992;319-341.
38. Gilman S: Positron emission tomographic studies of cerebellar disorders. In: Lechtenberg R, Ed, *Handbook of Cerebellar Disease*. New York:Marcel Dekker, Inc. 1993;131-134.
39. Gilman S: Olivopontocerebellar atrophy. In: Smith B, Adelman G, Eds, *Neuroscience Year, Supplement 3 to the Encyclopedia of Neuroscience*. Boston: Birkhauser 1993;109-110.
40. Gilman S: Ataxia and disorders of balance and gait. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, Eds, *Harrison's Principles of Internal Medicine, Thirteenth Edition*. New York:McGraw-Hill 1994;125-130.
41. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St. Laurent RT: Benzodiazepine receptor binding in the cerebellum in multiple system atrophy and olivopontocerebellar atrophy studied with positron emission tomography. In: Battistin L, Scarlato G, Curaceni T, Ruggieri S, Eds, *Advances in Neurology, Volume 69*, New York: Lippincott-Raven, 1996;459-466.
42. Gilman S: Techniques and capabilities in PET. In: Toole J, Good DC, Eds, *Imaging in Neurologic Rehabilitation*. New York: Demos Vermande 1996; 23-27.
43. Gilman S: Research trends in Alzheimer's disease and other neurodegenerative disorders: the Michigan Alzheimer's Disease Research Center. In: Vellas B, Fitten LJ, Dubois B, Albarede JL, Eds, *Alzheimer's Disease. Facts Research and Intervention in Gerontology* Paris, Serdi Publisher, 1996;95-109.
44. Gilman S: Clinical assessment of patients with dementia. In: Khachaturian ZS, Radebaugh TS, Eds, *Alzheimer's Disease: Cause(s), Diagnosis, Treatment, and Care*, Boca Raton: CRC Press 1996; 85-95.
46. Gilman S: Clinical features and treatment of cerebellar disorders. In: Watts RL, Koller WE, Eds, *Movement Disorders: Neurologic Principles and Practice*. New York: McGraw-Hill 1997;577-585.
45. Gilman S: Olivopontocerebellar atrophy. In: Smith B, Adelman G, Eds, *Encyclopedia of Neuroscience, 2nd edition (CD-ROM)*. Amsterdam, Elsevier Science 1998.
47. Gilman S: Cerebellar Disorders. In: Rosenberg R, Pleasure DE, Eds, *Comprehensive Neurology*, 2nd edition. New York: John Wiley & Sons 1998;415-433
48. Gilman S: Multiple System Atrophy. In: Jankovic J, Tolosa E, Eds, *Parkinson's Disease and Movement Disorders*, 3rd edition. Baltimore, Maryland Williams and Wilkins, 1998;245-262.
49. Gilman S, Adams KM, Koeppe RA, Junck L, Johnson-Greene D, Kluin KJ, Heumann ML: Cerebral injury from severe chronic alcoholism. In: Gomberg ESL, Hegedus AM, Zucker RA, Eds, *Alcohol Problems and Aging*, Research Monograph 33, National

- Institute on Alcohol Abuse and Alcoholism, US Department of Health and Human Services, 1998, 145-168.
50. Gilman S: Denny-Brown, Derek Ernest. In: Garraty JA, Carnes MC, *American National Biography*, New York, Oxford University Press, 1999, 448-449.
 51. Gilman S, Heumann M, Junck, L: Neurodegenerative disorders of the cerebellum. In: Mazziotta JC, Toga A, Frackowiak, RJC, Eds, *Brain Mapping: The Disorders*. San Diego, California, Academic Press, 2000.
 52. Gilman S, Gelb DJ: The Cerebellum. In: Joynt R, Griggs R, *Clinical Neurology* Philadelphia, Lippincott Williams & Wilkins, 2000.
 53. Vilensky JA, Gilman S: Involuntary muscle contractions detected by electromyography (EMG). In: Latash ML, Zatsiorsky VM, Eds, *Classics in Movement Science*. Champaign IL, Human Kinetics, 2001.
 54. Gilman S: Multiple System Atrophy. In: Jankovic JJ, Tolosa E, Eds, *Parkinson's Disease and Movement Disorders*, 4rd edition. Philadelphia, Lippincott Williams and Wilkins 2002, 170-184.
 55. Shults C, Gilman S: Multiple system atrophy. In: Pulst S-M, Ed, *Genetics of Movement Disorders*, San Diego, Academic Press 2003, 213-229.
 56. Gilman S: Sporadic olivopontocerebellar atrophy and the dominantly inherited spinocerebellar ataxias. In: Smith B, Adelman G, Eds, *Encyclopedia of Neuroscience, 3rd edition (Web-based)*. Amsterdam, Elsevier Science 2004.
 57. Gilman S: Clinical features and treatment of cerebellar disorders. In: Watts RL, Koller WE, Eds, *Movement Disorders: Neurologic Principles and Practice, 2nd Edition*. New York: McGraw-Hill 2004, 723-735.
 58. Gilman S: Gait disorders. In: Rowland LW, Ed, *Merritt's Neurology 11th Edition*. Philadelphia: Lippincott Williams & Wilkins 2005, 56-60.
 59. Gilman S: Parkinsonian syndromes. *Clin Geriatr Med* 2006;22:827-842.
 60. Gilman S: Chapter 13 Gait disorders. In: Rowland LW, Pedley T, Eds, *Merritt's Neurology 12th Edition*. Philadelphia: Lippincott Williams & Wilkins 2010, 58-61.
 61. Gilman S, Vilensky J: Derek Ernest Denny-Brown (1901-1981): The Man and His Role in 20th Century Neurology. In: Dawson DM, Sabin T, Eds, *The Neurological Unit, Boston City Hospital 2010* (In Press).
 62. Vilensky JA, Gilman S: Introduction. In: Vilensky JA, Ed, *Encephalitis Lethargica*. Oxford: Oxford University Press 2011, 3-7.
 63. Vilensky JA, Gilman S: Encephalitis lethargic during the epidemic period. In: Vilensky JA, Ed, *Encephalitis Lethargica*. Oxford: Oxford University Press 2011, 8-38.
 64. Vilensky JA, Gilman S, Duvoisin RC, Mukhamedzyanov RZ: Post-epidemic period encephalitis lethargica. In: Vilensky JA, Ed, *Encephalitis Lethargica*. Oxford: Oxford University Press 2011, 83-139.
 65. Vilensky JA, Gilman S: Secondary chronic encephalitis lethargica. In: Vilensky JA, Ed, *Encephalitis Lethargica*. Oxford: Oxford University Press 2011, 161-182.
 66. Vilensky JA, Gilman S, Duvoisin RC: Oliver Sacks, *Awakenings*, and postencephalitic parkinsonism. In: Vilensky JA, Ed, *Encephalitis Lethargica*. Oxford: Oxford University Press 2011, 183-205.
 67. Vilensky JA, Gilman S: Final thoughts. In: Vilensky JA, Ed, *Encephalitis Lethargica*. Oxford: Oxford University Press 2011, 298-305.

68. Wenning GK, Krismer F, Gilman S. Multiple system atrophy. In: Manto M-U, Ed, Handbook of Cerebellum and Cerebellar Disorders, New York, Springer 2011 (In press).

Books

1. Gilman S, Bloedel JR, Lechtenberg R: Disorders of the Cerebellum. Philadelphia: F.A. Davis Co., 1981.
2. Gilman S, Winans S: Manter and Gatz's Essentials of Clinical Neuroanatomy and Neurophysiology, 6th Edition. Philadelphia: F.A. Davis Co., 1982.
3. Gilman S, Newman S: Manter and Gatz's Essentials of Clinical Neuroanatomy and Neurophysiology, 7th Edition. Philadelphia: F.A. Davis Co., 1987.
4. Gilman S, Newman S: Manter and Gatz's Essentials of Clinical Neuroanatomy and Neurophysiology, 8th Edition. Philadelphia: F.A. Davis Co., 1992.
5. Mazziotta JC, Gilman S (eds.): Clinical Brain Imaging: Principles and Applications. Philadelphia: F.A. Davis Co. 1992.
6. Gilman S, Newman S: Manter and Gatz's Essentials of Clinical Neuroanatomy and Neurophysiology, 9th Edition. Philadelphia: F.A. Davis Co., 1996.
7. Gilman S (ed.): Clinical Examination of the Nervous System. New York: McGraw-Hill, 2000.
8. Gilman S, Newman S: Manter and Gatz's Essentials of Clinical Neuroanatomy and Neurophysiology, 10th Edition. Philadelphia: F.A. Davis Co., 2003.
9. Gilman S. (ed): Neurobiology of Disease. San Diego: Academic Press: 2007.
10. Gilman S. (ed): Oxford American Handbook of Neurology. New York: Oxford University Press: 2010. 462 p.

Other Media

Letters

1. Gilman S: Temporary psychosis after heart operations. New Engl J Med 1965; 273:990.
2. Gilman S: Independent neurology. New Engl J Med 1974; 291:1197.
3. Gilman S, Foster NL: "The alzheimerization of aging": a response. The Gerontologist 1996; 36:9-10.
4. Gilman S, Sima AF, Junck L, Kluin KJ, Koeppe RA, Lohman ME, Little R: Reply to "Glial and cytoplasmic inclusions in familial olivopontocerebellar atrophy". Ann Neurol 1996; 40:820.
5. Gilman S, St. Laurent RT, Koeppe RA, Junck L, Kluin KJ, Lohman M: Reply to "SPECT in OPCA". Neurology 1996; 47:311-312.
6. Gilman S, Quinn NP: Reply to "MRI in sporadic olivopontocerebellar atrophy and striatonigral degeneration". Neurology 1997; 48:790-792.
7. Vilensky JA, Gilman S: Renaming the "Henneman Size Principle". Science 1998;280:2031.
8. Gilman S: Imaging the brain. N Engl J Med 1998;339:407-409.
9. Mintzer S, Hickenbottom S, Gilman S: Parkinsonism after taking ecstasy. N Engl J Med 1999;340:1443.

10. Mintzer S, Hickenbottom S, Gilman S: More about parkinsonism after taking ecstasy. *N Engl J Med* 1999;341:1400-1401.
11. Vilensky JA, Gilman S: Comment on "The significance of supraspinal control of reflex actions". *Brain Res Bull* 2001;54:585-586.
12. Kluin KJ, Gilman S, Foster NL, D'Amato CJ, Bluemlein L, Little R, Sima AAF, Bruch LA, Johanns J. Reply to "Neuropathologic correlates of dysarthria in progressive supranuclear palsy". *Arch Neurol* 2001;58:1499-1500.
13. Gilman S, Koeppe R, Little R, An, H, Junck L, Giordani B, Persad C, Heumann M, Wernette K. Reply to "Dementia in dementia with Lewy bodies may not be attributable to Alzheimer pathology". *Ann Neurol* 2004;56:604.
14. Schenk D, Gilman S. What do people at risk for Alzheimer disease think about surrogate consent for research? *Neurology* 2006;66:1785-1786.
15. Grundman M, Gilman S, Black RS, Fox NC, Koller M, Koepsell TD, Chi Y-Y, Ramos EM, Lee WW, Kukull WA. An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease. *Neurology* 2008;71:697-698.
16. Laskowitz DT, Kolls BJ, Salloway SP, Black R, Sperling R, Fox N, Gilman S, Schenk D, Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. *Neurology* 2010;74:2026-2027.

Abstracts

1. Gilman S, Gernandt BE: Proprioceptive and cerebellar control of vestibulospinal influences. *Neurology* 1959;9:204.
2. Gilman S, Gernandt BE: Spinal inhibition by brain stem activation. *Neurology* 1960;10:426.
3. Gilman S, Gernandt BE: Functional investigation of descending vestibular pathways. *Anat Rec* 1960;136-137.
4. Gilman S, MacFadyen DJ, Denny-Brown D: Postural changes resulting from carotid amytal injection. *Tr Am Neurol Assn* 1962;87:40-43.
5. Denny-Brown D, Gilman S: Behavioral effects of dorsal column lesions. *Tr Am Neurol Assn* 1963;88:95-98.
6. Denny-Brown D, Gilman S, Van Der Meulen J: Patterns of cortical ablations leading to dystonic postures. *Tr Am Neurol Assn* 1964;89:117-121.
7. Denny-Brown D, Gilman S: Depression of gamma innervation by cerebellectomy. *Tr Am Neurol Assn* 1965;90:96-101.
8. Denny-Brown D, Gilman S, Van Der Meulen J: Dystonic motor disorder resulting from cortical lesions in the monkey. *Excerpta Medica (8th Int Cong Neurol)* 1965;94:132-133.
9. Denny-Brown D, Gilman S: Dystonic postures in relation to various levels of decerebration. *Tr Am Neurol Assn* 1966;91:68-72.
10. Gilman S, McDonald WI: The cerebellar efferent pathways for facilitation of muscle spindle activity. *Neurology* 1967;17:300.
11. Gilman S: The nature of decerebellate alpha motoneuron hyperexcitability. *Neurology* 1968;18:303.
12. Gilman S: A mechanism underlying cerebellar hypotonia. *Tr Am Neurol Assn* 1968;93:213-215.
13. Gilman S: Fusimotor fiber responses in the decerebellate cat. *Neurology* 1969;19:308.

14. Gilman S: An experimental analysis of cerebellar hypotonia. *Excerpta Medica (9th Int Cong Neurol)* 1969;193:624.
15. Gilman S, Ebel HC: The excitation pattern of fusimotor and alpha-motor fibers after cerebellar ablation. *Tr Am Neurol Assn* 1969;94:271-273.
16. Copack P, Potegal M, Krauthamer G, Gilman S: Vestibular projections to the caudate nucleus. *Physiologist* 1970;13:171.
17. Gilman S, Marco LA: Motor disorders following medullary pyramidal tract section in the monkey. *Tr Am Neurol Assn* 1970;95:108-113.
18. Marco LA, Sommers D, Ebel HC, Gilman S: Effect of cerebellar agenesis on muscle spindle afferent responses in cat. *XXV Int Cong Physiol Sci, Munich* 1971.
19. Gilman S, Marco LA, Lieberman JS: Experimental hypertonia in the monkey: Interruption of pyramidal or pyramidal-extrapyramidal cortical projections. *Tr Am Neurol Assn* 1971;96:162-168.
20. Gilman S, Cote LJ, Marco LA, Yahr MD, Wolf A: Biochemical changes in neostriatum after 6-hydroxydopamine implantation in brainstem of monkey. *J Neuropath Exp Neurol* 1972;31:167.
21. Marco L, Copack P, Gilman S: Intrinsic links of caudate neurons. *Fed Proc* 1972;31:403.
22. Lieberman JS, Copack P, Gilman S: Effects of focal freezing in ventrolateral nucleus and pulvinar on muscle spindle afferent responses. *Neurology* 1972;22:438.
23. Dafny N, Gilman S: Effects of L-DOPA and reserpine on evoked responses from basal ganglia of freely behaving rats. *Soc Neurosci* 1972;129.
24. Copack P, Lieberman JS, Gilman S: Alpha motoneuron responses to natural stimuli in experimental hypertonia. *Tr Am Neurol Assn* 1972;97:112-115.
25. Dauth G, Dafny N, Marco L, Glusman M, Gilman S: Modification of unit activity in hypothalamus and reticular formation by sensory and central stimulation. *Soc Neurosci* 1972;187.
26. Marco L, Edelson AM, Gilman S: Unit responses in anterolateral hypothalamus to local stimulation. *Physiologist* 1972;15:208.
27. Cooper IS, Amin I, Gilman S: The effect of chronic cerebellar stimulation upon epilepsy in man. *Tr Am Neurol Ann* 1973;98:192-196.
28. Gilman S: Experimental hypotonia from CNS lesions. *Excerpta Medica (10th Int Cong Neurol)* 1973;296:142.
29. Copack P, Felman E, Lieberman J, Gilman S: Differences in proximal and distal conduction velocities of medial gastrocnemius nerve fibers. *Soc Neurosci* 1974; 177.
30. Gilman S: Mechanisms of cerebellar influence on motor control. *Proc Int Cong Physiol Sci* 1974;10:144-145.
31. Gilman S, Copack PB, Lieberman JS: Alpha motoneuron responses to natural stimuli in decerebellate cats. *Proc Int Cong Physiol Sci* 1974;11:156.
32. Chutorian AM, Gilman S: Isolated pallanesthesia and ataxia after chronic infantile polyneuropathy. *Neurology* 1975;25:388.
33. Gilman S, Dauth GW, Tennyson VM, Kremzner LT, Defendini R: Morphological and biochemical effects of chronic cerebellar stimulation in monkeys. *Arch Neurol* 1975;32:347.
34. Correll JW, Gilman S: Chronic cerebellar stimulation for treatment of intractable convulsive disorders in man. *J Neurosurg* 1975;42:493.

35. McKeough DM, Gilman S: Differential effects of basal ganglia and cerebellar lesions on fusimotor activity. *Soc Neurosci* 1975; 298.
36. Abraham LS, Blum P, Gilman S: Multi-modal responses of cells in the medial geniculate body of the cat. *Soc Neurosci* 1975;342.
37. Dauth GW, Dell S, Gilman S: Cerebellar cortical neuronal responses to surface stimulation. *Neurology* 1976;26:362.
38. Salcman M, Correll J, Defendini R, Gilman S: Morphologic abnormalities in cerebellar biopsies of epileptic patients. *Arch Neurol* 1976;33:383.
39. Gilman S, Carr D, Hollenberg J: Limb trajectories after cerebellar ablation and deafferentation in the monkey. *Arch Neurol* 1976;33:390.
40. Dauth GW, Dell S, Gilman S: Purkinje cell responses to transfolial stimulation. *Soc Neurosci* 1976; 366.
41. Day N, Blum P, Carpenter MB, Gilman S: Thalamic components of ascending vestibular projections. *Soc Neurosci* 1976;1527.
42. Lechtenberg R, Gilman S: Cerebellar lesions associated with speech disorders. *Ann Neurol* 1977; 498.
43. Bromberg MB, Gilman S: Effects of cerebellar lesions on rubral multiunit activity, posture and locomotion in chronic cats. *Satellite Symposium on Neurophysiological Mechanisms of Locomotion, Paris, France, July 1977.*
44. Lechtenberg R, Gilman, S: Cerebellar lesions associated with speech disorders. *Tr Am Neurol Assn* 1977;102:42-45.
45. Dauth GW, Yokoyama T, Gilman S: The effects of transfolial stimulation on fastigial neurons. *Neurology* 1979;29:597.
46. Dauth GW, Gilman S, Frey K, Penney J, Agranoff B: [14C]-2-deoxyglucose uptake in monkeys with hypotonic hemiplegia after precentral cortical ablation. *Soc Neurosci* 1979; 367.
47. Dauth GW, Gilman S, Frey K, Penney J: [14C]-2-deoxyglucose uptake in monkeys with hypotonic hemiplegia after precentral or postcentral lesions. *Neurology* 1980;30:407.
48. Kornhauser D, Bromberg MB, Gilman S: The effect of unilateral fastigial lesions on static and dynamic responses of muscle spindle primary afferents in the cat. *Soc Neurosci* 1980;466.
49. Gilman S, Dauth GW, Frey K, Penney JB: Asymmetries of glucose utilization in the basal ganglia of hypotonic and hypertonic hemiplegic monkeys after precentral cortical ablation. *Neurology* 1981;31:150.
50. Young AB, Penney JB, Bromberg MB, Dauth GW, Gilman S: L glutamate uptake decreases in lumbar and cervical spinal cord of monkey contralateral to sensorimotor ablations. *Neurology* 1981;31:150.
51. Dauth GW, Frey K, Gilman S: Low cost microcomputer based densitometer system for quantitative autoradiography. *Soc Neurosci* 1981;501.
52. Gilman S, Dauth GW, Frey K, Penney JB: Effects of precentral cortical lesions on glucose utilization in the deep cerebellar and related nuclei in the monkey. *Soc Neurosci* 1981;785.
53. Gilman S, Kluin K: Speech disorders in cerebellar disease. *Neurology* 1984;34:187.
54. Aldrich MS, Alessi AG, Beck RW, Gilman S: Cortical blindness in adults: etiology, diagnosis, and prognosis. *Ann Neurol* 1984;16:115.

55. Gebarski SS, Gilman S, Young AB, Hood T, Aisen A: Neuroradiology of movement disorders: X-ray computed tomography, positron emission tomography, and magnetic resonance imaging. Amer Roentgen Ray Soc 1985.
56. Levine SR, Twyman RE, Gilman S: The role of anticoagulation in cavernous sinus thrombosis. Neurology 1985;35:215.
57. Abou-Khalil BW, Siegel GJ, Hichwa RD, Sackellares JC, Gilman S: Topography of glucose hypometabolism in epilepsy of mesial temporal origin. Ann Neurol 1985;18:151-152.
58. Shimoyama I, Dauth GW, Gilman S, Frey KA, Penney JB: Local glucose metabolic rate in primate thalamus during recovery from unilateral ablation of cerebral cortical areas 4 and 6. Soc Neurosci 1985;1089.
59. Foster NL, VanDerSpek A, Sackellares JC, Aldrich MS, Hichwa RD, Gilman S, Agranoff BW: The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease. Soc Neurosci 1985;1126.
60. Aldridge JW, Gilman S, Dauth GW: Changes in spontaneous single unit activity in the putamen following area 4 and 6 ablation in primates. Soc Neurosci 1985;684.
61. Gilman S, Markel DS, Koeppe R, Junck L, Hichwa R: Cerebellar hypometabolism in olivopontocerebellar atrophy detected by positron emission tomography. Neurology 1986;36:230.
62. Junck L, Gilman S, Hichwa R, Young AB, Markel DS, Ehrenkaufer RLE: PET studies of local cerebral glucose metabolism in idiopathic torsion dystonia. Neurology 1986;36:182.
63. Junck L, VanDerSpek A, Gilman S, Hichwa RD, Agranoff BW, Frey KA: The barbiturate contrast method for detection of brain infarcts by positron emission tomography. Neurology 1986;36:229.
64. Berent S, Sackellares JC, Abou-Khalil B, Gilman S, Siegel G, Hichwa R, Hutchins G: PET studies of cerebral glucose metabolic activity in temporal lobe epilepsy: The functional implications of lateralized hypometabolism. Neurology 1986;36:337.
65. Sackellares JC, Abou-Khalil BW, Siegel GJ, Gilman S, Hichwa R, Hutchins G, Berent S: PET studies of interictal, ictal, and postictal changes in local cerebral blood flow in temporal lobe epilepsy. Neurology 1986;36:338.
66. Foster NL, Gilman S, Berent S, Hichwa RD: Distinctive patterns of cerebral cortical glucose metabolism in progressive supranuclear palsy and Alzheimer's disease studied with positron emission tomography. Neurology 1986;36:338.
67. Aldridge JW, Gilman S, Dauth GW: Decreased spontaneous bursting in striatal neurons after lesions of cerebral cortical areas 4 and 6 in primates. Proc Internat Union Physiol Sci 1986;26:519.
68. Koeppe RA, Gilman S, Markel DS, Junck L, Hichwa RD: Local cerebral metabolism in patients with olivopontocerebellar atrophy (OPCA) as studied by PET and 2-FDG. J Nucl Med 1986;26:920.
69. Hichwa RD, Hutchins GD, Sackellares JC, Abou-Khalil BW, Siegel GJ, Berent S, Gilman S: Determination of LCBF during the evolution of partial seizures in patients with temporal lobe epilepsy. J Nucl Med 1986;26:902.
70. Gilman S, Markel DS, Koeppe RA, Junck L, Gebarski SS, Hichwa R: A comparison of CT and PET findings in olivopontocerebellar atrophy. Ann Neurol 1986;20:121.
71. Aldridge JW, Gilman S, Dauth GW: Changes in spontaneous single unit activity in the globus pallidus following area 4 and 6 ablation in primates. Soc Neurosci 1986;651.

72. Dauth GW, Shimoyama I, Hollingsworth Z, Penney JB, Gilman S, Aldridge JW, Young AB: Distribution of glutamate binding in primate brain. *Soc Neurosci* 1986;810.
73. Gebarski SS, Gilman S: The initial diagnosis of MS: Clinical impact of MRI. American Society of Neuroradiology Annual Meeting, 1986.
74. Kluin K, Gilman S, Markel D, Koeppe RA, Junck LR: Speech disorders in olivopontocerebellar atrophy correlate with regional abnormalities of cerebral metabolic activity studied with PET. *Neurology* 1987;37:268.
75. Berent S, Foster NL, Gilman S, Hichwa R, Lehtinen S: Patterns of cortical 18F-FDG metabolism in Alzheimer's and progressive supranuclear palsy patients are related to the types of cognitive impairments. *Neurology* 1987;37:172.
76. Foster NL, Berent S, Brown MB, Gilman S, Hichwa RD: Cerebral cortical metabolism reflects performance on the Wechsler adult intelligence scale. *Neurology* 1987;37:169.
77. Foster NL, Gilman S, Berent S, Brown MB, Hichwa RD: Glucose hypometabolism in progressive supranuclear palsy is not limited to frontal cortex. *Ann Neurol* 1987;22:123.
78. Buchtel HA, Sackellares JC, Abou-Khalil BW, Berent S, Gilman S, Siegel GJ, Hichwa RD, Hutchins GD, Hood TW: Glucose metabolism in mesial temporal region as a predictor of memory performance during the carotid sodium amytal test. *Epilepsia* 1987;28:619.
79. Jaeger D, Sachdev RNS, Dauth GW, Gilman S, Aldridge JW: Cross-correlation analysis of globus pallidus and entopeduncular unit activity in the awake cat and the effects of lesioning neostriatum. *Soc Neurosci* 1987;13:981.
80. Foster NL, Morin EM, Kuhl DE, Gilman S: Metabolic activity in the basal ganglia and thalamus differs in progressive supranuclear palsy and Alzheimer's disease. *Neurology* 1988;38:369.
81. Berent S, Giordani B, Gilman S, Junck L, Lehtinen S, Markel D, Boivin M, Kluin K, Parks R: A quantitative analysis of cognitive, intellectual, and emotional function in olivopontocerebellar atrophy. *Neurology* 1988;38:285.
82. Gilman S, Junck L, Markel DS, Koeppe RA, Kluin KJ: Cerebellar and thalamic hypometabolism in Friedreich's ataxia studied with PET. *Neurology* 1988;38:366.
83. Rosenthal G, Gilman S, Koeppe RA, Kluin KJ, Markel DS, Gebarski SS, Junck L: Severity of motor dysfunction in olivopontocerebellar atrophy is related to cerebral metabolic rate studied with positron emission tomography. *Neurology* 1988;38:365.
84. Gilman S, Adams K, Koeppe RA, Berent S: Cerebellar hypometabolism in alcoholic cerebellar degeneration studied with FDG and PET. *Neurology* 1988;38:365.
85. Young AB, Penney JB, Richfield E, Albin R, Dauth G, Gilman S: Anatomy of excitatory amino acid receptors in developing and adult mammalian nervous system. *Neurochem Int* 1988;12 (Suppl. 1):2.
86. Penney JB, Young AB, Bromberg M, Dauth G, Gilman S: Excitatory amino acids and their receptors in motor pathways. *Neurochem Int* 1988;12 (Suppl. 1):11.
87. Sachdev RNS, Hekmatpanah C, Jaeger D, Gilman S, Aldridge JW: A comparison of auditory and visual go-cues on single unit activity in thalamus. *Soc Neurosci* 1988;14:719.
88. Jaeger D, Dauth GW, Gilman S, Aldridge JW: Single unit activity of primate caudate nucleus in a precue task. *Soc Neurosci* 1988;14:719.

89. Giordani B, Berent S, Gilman S, Boivin MJ, Lehtinen S, Koeppe RA, Markel DS, Junck L, Kluin KJ: Subcortical indices of hypometabolism in OPCA and their relationship to neuropsychological functioning. *J Nucl Med* 1988;29:913.
90. Albin RL, Cha JJ, Makowiec RL, Young AB, Gilman S, Plaitakis A: Autoradiographic analysis of cerebellar amino acid neurotransmitter receptors in olivopontocerebellar atrophy and Friedreich's ataxia. *Neurology* 1989;39:423.
91. Markel DS, Gilman S, Koeppe RA, Kluin KJ, Junck L: Correlation of clinical abnormalities with glucose metabolic rate in sporadic and genetic olivopontocerebellar atrophy studied with positron emission tomography. *Neurology* 1989;39:163.
92. Rosenthal G, Koeppe RA, Gilman S, Lopez R, Junck L, Gebarski SS: Hypometabolism per gram of tissue in OPCA detected following a quantitative correction for cerebral atrophy in CT scans. *Neurology* 1989;39:164.
93. Junck L, Moen JG, Foster NL, Gilman S, Kuhl DE: Cerebellar metabolic asymmetry in degenerative neurologic disorders studied with PET. *Neurology* 1989;39:164.
94. Gilman S, Junck L, Markel DS, Koeppe RA, Kluin KJ: Cerebral glucose hypermetabolism in Friedreich's ataxia studied with positron emission tomography. *J Cereb Blood Flow & Metab* 1989;9:S19.
95. Junck L, Moen JG, Bluemlein L, Foster NL, Agranoff BW, Gilman S, Young AB, Rothley JR, Betley AT, Koeppe RA, Hutchins G, Hichwa RD, Berent S, Kuhl DE: Cerebral glucose metabolism in normal aging studied with PET. *J Cereb Blood Flow & Metab* 1989;9:S524.
96. Koeppe RA, Rosenthal G, Gilman S, Lopez R, Junck L, Gebarski SS: Correction for effects of tissue atrophy in PET studies using quantitative anatomic imaging. *J Cereb Blood Flow & Metab* 1989;9:S197.
97. Berent S, Giordani B, Boivin S, Lehtinen S, Amato DA, Junck L, Markel D, Kluin K, Gilman S: The relationship among intellectual, motor, and metabolic measures in Friedreich's ataxia. *J Cereb Blood Flow & Metab* 1989;9:S328.
98. McDonald JW, Hood T, Sackellares JC, Garofalo EA, Abou-Khalil BW, McKeever PE, Gilman S, Johnston MV: Temporal lobe epilepsy: excitatory and inhibitory amino acid receptor binding changes in excised hippocampus. *Epilepsia* 1989;30(5):719.
99. McDonald JW, Hood T, Sackellares JC, Garofalo EA, Abou-Khalil BW, McKeever PE, Gilman S, Johnston MV: Alterations in excitatory amino acid and GABA receptor binding in excised hippocampus from patients with temporal lobe epilepsy. *Ann Neurol* 1989;26:444.
100. Johnston MV, McDonald JW, Hood T, Sackellares JC, Garofalo E, McKeever PE, Troncoso J, Gilman S: Elevated NMDA receptor and reduced GABA receptor binding in hippocampus (HIP) from patients with temporal lobe epilepsy (TLE). *Soc Neurosci* 1989;15:1215.
101. Foster NL, Gilman S, Morin E, Markel D, Berent S: The pattern of cerebral hypometabolism studied with positron emission tomography is similar in sporadic and familial Alzheimer's disease. *Ann Neurol* 1989;26:135.
102. Jaeger D, Gilman S, Aldridge JW: A comparison between primate caudate nucleus and putamen single unit activity in a precued reaching task. *Soc Neurosci* 1989;15:284.
103. Kluin KJ, Foster NL, Gilman S, Berent S: Speech disorders in progressive supranuclear palsy. *Neurology* 1990;40:424.

104. Gilman S, Junck L, Gebarski SS, Kluin KJ, Markel DS, Koeppe RA: Friedreich's ataxia: comparison of clinical, CT, and PET-FDG findings. *Neurology* 1990;40:155.
105. Gilman S, Koeppe RA, Markel DS, Junck L, Kluin KJ: Relationship between cerebral blood flow and glucose metabolic rate in olivopontocerebellar atrophy studied with positron emission tomography. *Neurology* 1991;41:225.
106. Gilman S, Holthoff V, Koeppe RA, Frey KA, Junck L, Kluin KJ, Brunberg J: Decreased cerebellar GABA/Benzodiazepine receptor binding in OPCA studied with [¹¹C]flumazenil and PET. *J Cereb Blood Flow Metab* 1991;11:S230.
107. Henry TR, Sackellares JC, Gilman S, Holthoff VA, Frey KA, Koeppe RA, Brunberg JA, Berent S, Young AB, Kuhl DE: Decreased mesial temporal [¹¹C]flumazenil binding with mesiolateral temporal hypometabolism in temporal lobe epilepsy. *J Cereb Blood Flow Metab* 1991;11:S412.
108. Berent S, Giordani B, Gilman S, Koeppe R, Lehtinen S, Junck L, Markel D, Kluin K: Measures of depression correlate with frontal lobe metabolism studied with PET in olivopontocerebellar atrophy. *Biological Psychiatry* 1991;29:5755.
109. Frey KA, Henry TR, Holthoff VA, Koeppe RA, Sackellares JC, Brunberg JA, Berent S, Gilman S, Kuhl DE: Comparison of regional glucose metabolism and in vivo benzodiazepine receptor binding in refractory temporal lobe epilepsy. *J Nucl Med* 1991;32:912.
110. Adams KM, Gilman S, Koeppe RA, Berent S, Kluin KJ, Brunberg JA, Kroll P, Lamberty GJ: Neuropsychological deficits are correlated with frontal hypometabolism in positron emission tomography studies of older alcoholic patients. *Alcohol Clin Exp Res* 1991;15:369.
111. Aldridge JW, Thompson JF, Walters EA, Groh JM, Gilman S: Neostriatal unit activity related to movement preparation in a go/no-go task in the cat. *Soc Neurosci* 1991;17:1572.
112. Aldridge JW, Thompson J, Walters EA, Gilman S: Functional convergence of unit activity related to movement preparation in a go/no-go task in the basal ganglia of the cat. *Proceedings of the International Brain Research Organization* 1991;143.
113. Turgeon SM, Albin RL, Gilman S: Development, pharmacology, distribution, and cellular localization of GABA_B binding in rat cerebellum. *Soc Neurosci* 1991;17:1579.
114. Vilensky JA, Gilman S, Moore A: Primate lesion film collections. *Soc Neurosci* 1991;17:1579.
115. Gilman S, Koeppe RA, Junck L, Kluin K, Lohman M: Extensive cerebral hypometabolism in multiple system atrophy detected with [¹⁸F]fluorodeoxyglucose and positron emission tomography. *Neurology* 1992;42:398-399.
116. Foster NL, Gilman S, Gelb DJ, Struble L, Giordani B, Berent S, Lohman M: Extrapyrmidal signs in probable Alzheimer's disease. *Neurology* 1992;42:200.
117. Henry TR, Frey KA, Sackellares JC, Ross DA, Koeppe RA, Buchtel HA, Brunberg JA, Gilman S, Berent S, Kuhl DE: Anterior mesial temporal benzodiazepine receptor decrease on [¹¹C]flumazenil PET agrees with multimodal localization of epileptogenesis in refractory complex partial seizures. *Neurology* 1992;42:297-298.
118. Adams KM, Gilman S, Koeppe RA, Dede D, Kluin K, Brunberg J, Berent S, Kroll P: Evaluation of benzodiazepine/GABA_A binding in alcoholic cerebellar degeneration

- patients using [¹¹C]flumazenil and positron emission tomography (PET). *ISBRA* 1992; 27(Suppl 1):56.
119. Burdette DE, Sakurai SY, Sackellares JC, Henry TR, Ross DA, Gilman S, Frey KA, Albin RL: GABA_A receptor binding and central benzodiazepine omega 1 and omega 2 receptor binding in mesial temporal lobe epilepsy. *Neurology* 1993; 43:A353-354.
 120. Henry TR, McKeever PE, Ross DA, Frey KA, Gilman S, Koeppe RA, Brunberg JA, Berent S, Kuhl DE, Sackellares JC. Hippocampal decreases in central benzodiazepine binding detected with [¹¹C]flumazenil positron emission tomography in hippocampal sclerosis. *Epilepsia* 1993; 34:126-127.
 121. Aldridge JW, Thompson JF, Meyer RC, Gilman S: Neostriatal lesions in the cat produce apraxia and changes in pallidal neuronal activity. *Soc Neurosci* 1993; 19:1586.
 122. Connell CM, Benedict CJ, Kole SL, Beane E, Holmes SB, Gilman S: Increasing coordination of the dementia service delivery network: development of the community outreach education program. *The Gerontologist*, 1993; 33:230.
 123. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St. Laurent RT: PET studies of cerebellar benzodiazepine receptors with [¹¹C]flumazenil show increased binding in MSA and decreased binding in OPCA. *Neurology* 1994; 44:A353.
 124. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St. Laurent RT: The pattern of cerebral glucose metabolism examined with positron emission tomography is different in multiple system atrophy and olivopontocerebellar atrophy. *Eleventh International Symposium on Parkinson's Disease, Rome* 1994.
 125. Kluin KJ, Gilman S, Lohman M, Junck L: Dysarthria of multiple system atrophy. *Neurology* 1994; 44:A150.
 126. Aldridge JW, Thompson JF, Gilman S: Neuronal activity related to sensory cues and movement in the subthalamic nucleus of the cat. *Soc Neurosci* 1994; 20:780.
 127. Meyer RC, Aldridge JW, Thompson JF, Gilman S: Neuronal activity in the cat entopeduncular nucleus related to conditioned visual stimuli and reward in a sequential movement task. *Soc Neurosci* 1994; 20:780.
 128. Connell CM, Benedict CJ, Kole SL, Avey H, Holmes SB, Gilman S. Michigan Alzheimer's Disease Outreach Education: A community development model. In CM Connell (Chair), *Community-based outreach education for Alzheimer's disease: Meeting the needs of underserved populations*. Gerontological Society of America 1994.
 129. Johnson-Greene D, Adams KM, Gilman S, Koeppe R, Kluin K, Junck L, Lohman M, Berent S. Frontal lobe hypometabolism measured using [¹⁸F]FDG PET in an older alcoholic patient. *Clin Neuropsychol* 1994; 8:359.
 130. Gilman S, Frey KA, Koeppe RA, Junck L, Little R, Vander Borcht T, Lohman M, Martorello S, Lee LC, Jewett DM, Kilbourn MR. Decreased striatal monoaminergic presynaptic terminals in OPCA and MSA demonstrated with [¹¹C]dihydrotetrabenazine and PET. *J Cereb Blood Flow Metab* 1995;15 (Suppl 1):S752.
 131. Frey KA, Koeppe RA, Kilbourn MR, Vander Borcht TM, Albin RL, Gilman S, Kuhl DE. Reduction of presynaptic monoaminergic vesicles in the striata of parkinsonian patients and in normal human aging. *J Cereb Blood Flow Metab* 1995;15 (Suppl 1):S38.
 132. Adams KM, Gilman S, Koeppe R, Johnson-Greene D, Kluin K, Junck L, Martorello, S, Lohman M. Decreased benzodiazepine receptor binding in the cingulate cortex of chronic

- alcoholic patients measured with [^{11}C]flumazenil and PET *Alcoholism Clin Exptl Res* 1995; 19:10A.
133. Benedict CJ, Connell CM, Kole SL, McGhan P, Holmes SB, Gilman S. Increasing coordination of the dementia service delivery network: implementation and evaluation of the community outreach education program. *Gerontological Society of America* 1995.
 134. Cook JA, Morecraft RJ, Vilensky JA, Gilman S. DC60: an example of one of the 450 cases that comprise the Denny-Brown Collection. *Soc Neurosci* 1995; 21:417.
 135. Vilensky JA, Gilman S. Utilization of available films and records of primates with central nervous system lesions: an example showing differential locomotor recovery in the hind and forelimbs. *Amer Assoc Physical Anthropol* 1995.
 136. Kirtley C, Vilensky JA, Gilman S, Morecraft R. Motor control toolbox: a neuroscience teaching resource. *Third Biennial Motor Control and Human Skill Workshop, Perth, Dec 2-3, 1995.*
 137. Johnson-Greene D, Adams KM, Gilman S, Koeppel R, Kluin K, Junck L, Berent S, Marks J, Martorello S, Lohman M, Dehring K: Cerebral metabolism and delayed memory performance among chronic alcoholics. *Clin Neuropsychologist* 1995; 9:274.
 138. Meyer RC, Aldridge JW, Thompson JF, Gilman S: Neuronal activity in the pallidum of the cat related to conditioned visual stimuli in a sequential movement task. *Soc Neurosci* 1995; 21:412.
 139. Vilensky JA, Gilman S, Dunn EA: Recovery of locomotion in monkeys occurs earlier in the hindlimbs than forelimbs after extensive unilateral cerebral ablations. *Soc Neurosci* 1995; 21:420.
 140. Johnson-Greene D, Adams KM, Anderson S, Ross S, Bergloff P, Gilman S, Koeppel R, Junck L, Kluin K, Martorello S, Lohman M, Berent S: Paired associate learning and cerebral metabolism measured using [^{18}F]FDG PET in chronic alcoholics. *J Int Neuropsychol Soc* 1996; 2:62.
 141. Foster NL, Sima AAF, D'Amato C, Bruch LA, Kluin K, Bluemlein LA, Little RJ, Johanns J, Gilman S: Cerebral cortical pathology in progressive supranuclear palsy is correlated with severity of dementia. *Neurology* 1996; 46:A363.
 142. Vilensky JA, Gilman S: Utilization of available films and records of primates with central nervous system lesions: an example showing differential locomotor recovery in the hindlimbs and forelimbs. *Am J Physical Anthropology* 1996; Suppl 22, p. 235.
 143. Vilensky JA, Gilman S: A modern appraisal of Denny-Brown's conceptions of grasping and avoiding. *Soc Neurosci* 1996; 22:1097.
 144. Gilman S, Foster NL, Minoshima S, Koeppel RA, Martorello SP, Heumann ML, Kuhl DE: Benzodiazepine receptor density in progressive supranuclear palsy studied with [^{11}C]flumazenil and PET. *Movement Disorders* 1997; 12 (Suppl 1):78.
 145. Robertson WM, Gilman S, Vilensky JA: The Denny-Brown collection: Recognition of progressive supranuclear palsy as a unique disorder in the decade before the clinicopathologic description. *Neurology* 1997; 48:A145.
 146. Gilman S, Koeppel RA, Junck L, Adams KM, Martorello SP: Decreased striatal monoaminergic terminals in severe chronic alcoholism detected with (+)[^{11}C]dihydrotrabenazine and positron emission tomography *Neurology* 1997; 48:A275.

147. Kluin KJ, Gilman S, Foster NL, Sima AAF, D'Amato C, Bruch LA, Bluemlein L, Little RJ, Johans J: Degeneration of substantia nigra pars compacta contributes to the dysarthria of PSP. *Neurology* 1997; 48:A97.
148. Adams KM, Gilman S, Johnson-Greene D, Koeppe RA, Junck L, Kluin KJ, Martorello S, Heumann M, Hill E: The significance of family history status in relation to neuropsychological test performance and cerebral glucose metabolism studied with positron emission tomography in older alcoholic patients. *Int Neuropsychol Soc* 1997; 3:1.
149. Giordani B, Persad CC, Messmer C, Sima AAF, Gilman S, Albin RL, Foster NL, Heumann ME, Berent S: Lewy body disease differs from Alzheimer's disease in neuropsychological profile. *J Int Neuropsychol Soc* 1997; 3:15.
150. Johnson-Greene D, Adams KM, Gilman S, Kluin KJ, Junck L, Martorello S, Heumann M: Impaired upper limb coordination and motor function in alcoholic cerebellar degeneration. *Int Neuropsychol Soc* 1997; 3:56.
151. Johnson-Greene D, Adams KM, Gilman S, Koeppe RA, Junck L, Kluin KJ, Martorello S, Heumann M: Effects of abstinence and relapse upon neuropsychological function and cerebral glucose metabolism studied with PET in severe chronic alcoholism. *Int Neuropsychol Soc* 1997; 3:2.
152. Vilensky JA, Cook JA, Gilman S, Morecraft RJ: Apraxia of hand movements in young monkeys after bilateral sensorimotor cortex lesions. *Soc Neurosci* 1997; 23:1108.
153. Gilman S, Koeppe RA, Junck L, Little R, Kilbourn MR, Kluin KJ, Heumann M, Martorello S: Striatal monoaminergic presynaptic terminals in multiple system atrophy studied with (+)[¹¹C]DTBZ and PET. *J Cereb Blood Flow Metab* 1997; 17 (Suppl) 1:S694.
154. Gilman S, Foster NL, Koeppe RA, Kilbourn MR, Heumann ML: Striatal monoaminergic presynaptic terminals in Alzheimer's disease studied with (+)[¹¹C]dihydrotetrabenazine and positron emission tomography. *J Neurol Sci* 1997; S150:S21.
155. Robertson WM, Gilman S, Vilensky JA, Whitman GT: The Denny-Brown Collection: treatment of Wilson's disease with British anti-Lewisite. *Neurology* 1998;50:A58.
156. Barnhart SW, Gilman S, Vilensky JA, Cook JA, Morecraft RJ: Postural reflexes in monkeys after cerebellar ablations. *Soc Neurosci* 1998;24:1407.
157. Growdon JH, Davies P, Gilman S, Khachaturian Z, Radebaugh T, Roses A, Selkoe DJ, Trojanowski JQ: Molecular and biochemical markers of Alzheimer's disease. Sixth International Conference on Alzheimer's Disease, Amsterdam, July 19, 1998.
158. Gilman S, Vilensky JA, Morecraft RW, Cook JA: Utilization of the Denny-Brown collection: Influences of natural stimulation on dystonic postures in humans. *Soc Neurosci* 1999;25:1594.
159. Hadden LE, Gilman S, Aldridge JW: Coincident spike activity in pairs of striatal neurons associated with reward, cue and movement in the cat. *Soc Neurosci* 1999;25:1928.
160. Vilensky JA, Gilman S: Primate motor cortex lesion studies: an annotated bibliography of pre-Medline studies. *Soc Neurosci*, 2001.
161. Suzuki M, Desmond TJ, Albin RL, Gilman S, Frey KA: Presynaptic Cholinergic and Dopaminergic Markers in Lewy Body Dementia. *Soc Neurosci* 2001;27:497.
162. Frey KA, Koeppe RA, Little R, An H, Junck L, Heumann M, Gilman S: VMAT2 PET imaging distinguishes Alzheimer's disease and dementia with Lewy bodies. *European J Nucl Med* 2002;29:S152.

163. Gilman S, Koeppe RA, Chervin R, Consens F, Little R, An H, Junck L, Heumann M: A correlation between REM sleep behavior disorder and striatal monoaminergic innervation in multiple system atrophy. *Movement Disorders* 2002;17:S166.
164. Vilensky, J.A., W.M. Robertson and S. Gilman. Denny-Brown and British Anti-Lewisite (BAL, [2,3-Dimercaptopropanol]): The first curative treatment for Wilson's Disease (Hepatolenticular Degeneration). *Journal of the History of the Neurosciences* 2002;11:417.
165. Kluin KJ, Heumann M, Gilman S. Differences between SCA-1 and SCA-3 in motor speech and swallowing. *Neurology* 2003;60:A472.
166. Frey KA, Koeppe RA, Little R, An H, Junck L, Heumann M, Gilman S. Vesicular monoamine transporter imaging distinguishes neurodegenerative disorders: Striatal binding of [¹¹C]DTBZ in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. *J Cereb Blood Flow Metab* 2003;23(Suppl 1):630.
167. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, Persad C, Heumann M, Wernette K. A comparison of FDG-PET and neuropsychological testing in differentiating Alzheimer's disease from dementia with Lewy bodies. *Neurobiol Aging* 2004;25:S467.
168. Gilman S; Koller M; Black RS; Jenkins L; Griffith SG; Fox NC; Eisner L; Kirby L; Boada M; Forette F; Orgogozo JM, for the AN1792(QS-21)-201 Study Team. Neuropsychological, CSF, and Neuropathological Effects of A-Beta Immunotherapy (AN1792) of Alzheimer's Disease in an Interrupted Trial. *Neurobiol Aging* 2004;25:S84.
169. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, and Koller M, for the AN1792(QS-21)-201 Study Team. Effects of A-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disease. *Neurobiol Aging* 2004;25:S84.
170. Lanska DJ, Vilensky JA, Gilman S. Experimental bilateral vestibulopathy in monkeys. *Neurology* 2004;62:A201.
171. Gilman S, Frey KA, Koeppe RA, Albin RL, Junck L, Heumann M, Wernette K. Differences between idiopathic Parkinson's disease and dementia with Lewy bodies detected with [¹¹C]dihydrotetrabenazine and positron emission tomography. *Mov Disord* 2004;19:S373.
172. Gilman S. Positron emission tomography and single photon emission computed tomography in the diagnosis of multiple system atrophy. *Functional Neurology* 2004;19:138.
173. Gilman S, Raffel DA, Koeppe RA, Little R, An H, Junck L, Heumann M. Cardiac sympathetic innervation in multiple system atrophy and progressive supranuclear palsy. *Mov Disord* 2004;19:1118.
174. Vilensky JA Gilman S. The contributions of Derek Denny-Brown, the Boston City Hospital, and Harvard University to 20th Century American neurology. *J Hist Neurosci* 2004;13:377.
175. Consens FB, Chervin RD, Koeppe RA, Little R, Liu S, Junck L, Angell K, Heumann M, Gilman S. Validation of a Polysomnographic Score for REM Sleep Behavior Disorder (RBD). *Sleep* 2005 Abstract 0777.
176. Vilensky JA, Gilman S, Goetz C. Motion picture images of movement disorders involving the head and neck in postencephalitic parkinsonism. *Clin Anat* 2005;18:643-644.

177. Burns JW, Consens FB, Little RJ, Angell KJ, Gilman S, Chervin RD. EMG variance during polysomnography as an assessment for REM sleep behavior disorder (RBD). *Sleep* 2006;29:A270.
178. Vilensky JA, Goetz CG, Gilman S. Movement disorders associated with encephalitis lethargica. *J Hist Neurosci* 2006;15:422-3.
179. Tanner CM, Kukull W, Shults C, Comyns K, Bhudhikanok GS, May S, Goldman SM, Meng C, Gilman S, Chade AR, Colcher A, Huang N, Jankovic J, Kasten M, Low P, Marshall F, Novak P, Ondo W, Racette B, Reich S, Sandroni P, Stern M, Wooten F. Head Injury with Amnesia and Risk of Multiple System Atrophy (MSA). *Neurology* 2007;68(12):A49.
180. Vilensky JA, Gilman S, McCall S. Was there a relationship between encephalitis and influenza. *J Hist Neurosci* 2008;17:251.
181. Gilman S, Wenning GK, Low PA, Brooks D, Mathias CJ, Trojanowski JQ, Wood N, Colosimo C, Dürr A, Fowler C, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Klau Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology* 2008;70:A229.
182. Gilman S, Wenning GK, Low PA, Brooks D, Mathias CJ, Trojanowski JQ, Wood N, Colosimo C, Dürr A, Fowler C, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Klau Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. *Mov Disord* 2008.
183. Vilensky JA, Gilman S. The Matheson patient files: what can they tell us about encephalitis lethargica. *Proceedings of the 12th Annual Meeting of the International Society for the History of Neurosciences (2008)*.
184. Pestana Knight EM, Gilman S, Selwa LM. Non-Convulsive Status Epilepticus during therapy with Tetrathiomolybdate in a patient with Wilson's disease: Case Report and Literature Review. *American Epilepsy Society (2008) Accepted for poster presentation*.
185. Honig LS, Gilman S, Morris K, Grundman M, Francis G. Safety profile of bapineuzumab in a phase 2 trial of mild-to-moderate Alzheimer's Disease (AD). *Neurology* 2009;72 (Suppl 3):A272.
186. Gilman S, Koeppe RA, Nan B, Wang, C-N, Junck L, Chervin R, Consens F, Bhaumik, A. Cerebral cholinergic deficits in parkinsonian syndromes. *Neurology* 2009;72 (Suppl 3):A145-A146.
187. Vilensky JA, Gilman S, McCall S. Encephalitis lethargica and postencephalitic parkinsonism: not a simple relationship. *Proceedings of the 13th Annual Meeting of the International Society for the History of Neurosciences (2009)*.
188. DeLeon AA, Ryan KA, Coulas T, Frey K, Albin R, Burke J, Gilman S, Giordani B. Resolving diagnostic inaccuracies in frontotemporal dementia: a role for [¹¹C]PIB scanning. *International Neuropsychological Society Annual Meeting Acapulco, Mexico (Submitted) 2010*.
189. Poewe W, Gilman S, Low P, Rascol O, Sampaio C, Weiss Y, Wenning G, Seppi K for the Rasagiline-for-MSA investigators. A randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the Parkinsonian subtype (MSA-P) *European Federation of Neurological Sciences (Submitted) 2010*.
190. Gilman S, Low P, May S, Tanner C, Stern M, Sandroni P, Reich S, Marshall F, Novak P, Jankovic J, Wooten GF, Racette B, Sletten D, Shults C. Prospective 5-year natural history

- study of probable multiple system atrophy (MSA) in 175 North American subjects. *Mov Disord* 2010;25(7):S498-499.
191. Iodice V, Lipp A, Ahlskog JE, Sandroni P, Fealey RD, Parisi JE, Matsumoto JY, Maraganore DM, Benarroch EE, Kimpinski K, Singer W, Gehrking TL, Gehrking JA, Sletten DM, Schmeichel AM, Bower JH, Gilman S, Low PA. Autopsy Confirmed Multiple System Atrophy (MSA) Cases: Mayo Experience and role of Autonomic Function Tests. *Mov Disord* 2010;25(70):S563.
 192. Poewe W, Gilman S, Low P, Rascol O, Sampaio C, Weiss Y, Wenning G, Seppi K for the Rasagiline-for-MSA investigators. A randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the Parkinsonian subtype (MSA-P): Baseline characteristics and enrolment status. International Movement Disorders Society Meeting, Buenos Aires, 2010.
 193. Gilman S, Bohnen N, Raffel D, Koeppe R, Frey K, Albin R, Bhaumik A. Severity of Cardiac Sympathetic Denervation Correlates with Trait Anxiety and Depression in Parkinson Disease. *Neurology* 2011 (Submitted). Confirmation number 942AAN11D1.
 194. Müller M, Bohnen N, Raffel D, Koeppe R, Bhaumik A, Albin R, Frey K, S. Gilman S. Striatal dopaminergic denervation and cardiac post-ganglionic sympathetic denervation have independent correlations with gait velocity in Parkinson's disease. *Neurology* 2011 (Submitted).
 195. Wong KK, Raffel DA, Koeppe RA, Frey KA, Bohnen NI, Gilman S. PET cardiac sympathetic imaging with ^{11}C -hydroxyephedrine in idiopathic Parkinson's disease. Society for Nuclear Medicine 2011 (Submitted).
 196. Müller M, Bohnen NI, Gilman S, Koeppe RA. Shape analysis method can be used for estimating striatal [^{11}C]-PMP k3 hydrolysis rate. Society for Nuclear Medicine 2011 (Submitted).